Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof

ABSTRACT

The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

RELATED APPLICATIONS

The present application is a divisional of U.S. application Ser. No. 09/735,934, filed Dec. 14, 2000, issued as U.S. Pat. No. 6,372,468, which claims priority to U.S. Provisional Application No. 60/232,633, filed Sep. 14, 2000.

FIELD OF THE INVENTION

The present invention is in the field of kinase proteins that are related to the protein kinase C subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins that effect protein phosphorylation and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Protein Kinases

Kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Uncontrolled signaling has been implicated in a variety of disease conditions including inflammation, cancer, arteriosclerosis, and psoriasis. Reversible protein phosphorylation is the main strategy for controlling activities of eukaryotic cells. It is estimated that more than 1000 of the 10,000 proteins active in a typical mammalian cell are phosphorylated. The high energy phosphate, which drives activation, is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc), cell cycle checkpoints, and environmental or nutritional stresses and is roughly analogous to turning on a molecular switch. When the switch goes on, the appropriate protein kinase activates a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.

The kinases comprise the largest known protein group, a superfamily of enzymes with widely varied functions and specificities. They are usually named after their substrate, their regulatory molecules, or some aspect of a mutant phenotype. With regard to substrates, the protein kinases may be roughly divided into two groups; those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual specificity and phosphorylate threonine and tyrosine residues. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The N-terminal domain, which contains subdomains I-IV, generally folds into a two-lobed structure, which binds and orients the ATP (or GTP) donor molecule. The larger C terminal lobe, which contains subdomains VI A-XI, binds the protein substrate and carries out the transfer of the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Subdomain V spans the two lobes.

The kinases may be categorized into families by the different amino acid sequences (generally between 5 and 100 residues) located on either side of, or inserted into loops of, the kinase domain. These added amino acid sequences allow the regulation of each kinase as it recognizes and interacts with its target protein. The primary structure of the kinase domains is conserved and can be further subdivided into 11 subdomains. Each of the 11 subdomains contains specific residues and motifs or patterns of amino acids that are characteristic of that subdomain and are highly conserved (Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Books, Vol 1:7-20 Academic Press, San Diego, Calif.).

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic-ADPribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The cyclic-AMP dependent protein kinases (PKA) are important members of the STK family. Cyclic-AMP is an intracellular mediator of hormone action in all prokaryotic and animal cells that have been studied. Such hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cyclic-AMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K. J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York, N.Y., pp. 416-431, 1887).

Calcium-calmodulin (CaM) dependent protein kinases are also members of STK family. Calmodulin is a calcium receptor that mediates many calcium regulated processes by binding to target proteins in response to the binding of calcium. The principle target protein in these processes is CaM dependent protein kinases. CaM-kinases are involved in regulation of smooth muscle contraction (MLC kinase), glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM kinase I phosphorylates a variety of substrates including the neurotransmitter related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) EMBO Journal 14:3679-86). CaM II kinase also phosphorylates synapsin at different sites, and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. Many of the CaM kinases are activated by phosphorylation in addition to binding to CaM. The kinase may autophosphorylate itself, or be phosphorylated by another kinase as part of a “kinase cascade”.

Another ligand-activated protein kinase is 5′-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) J. Biol Chem. 15:8675-81). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

The mitogen-activated protein kinases (MAP) are also members of the STK family. MAP kinases also regulate intracellular signaling pathways. They mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S. E. and Weinberg, R. A. (1993) Nature 365:781-783). MAP kinase signaling pathways are present in mammalian cells as well as in yeast. The extracellular stimuli that activate mammalian pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1).

PRK (proliferation-related kinase) is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaroytic cells (Li, B. et al. (1996) J. Biol. Chem. 271:19402-8). PRK is related to the polo (derived from humans polo gene) family of STKs implicated in cell division. PRK is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation. Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.

The cyclin-dependent protein kinases (CDKs) are another group of STKs that control the progression of cells through the cell cycle. Cyclins are small regulatory proteins that act by binding to and activating CDKs that then trigger various phases of the cell cycle by phosphorylating and activating selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to the binding of cyclin, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue.

Protein tyrosine kinases, PTKs, specifically phosphorylate tyrosine residues on their target proteins and may be divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane protein-tyrosine kinases are receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor and other specific proteins. Growth factors (GF) associated with receptor PTKs include; epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Such receptors that function through non-receptor PTKs include those for cytokines, hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes.

Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells where their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Carbonneau H and Tonks N K (1992) Annu. Rev. Cell. Biol. 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

Protein Kinase C

Protein kinase C (PKC) proteins are members of the STK family. Protein kinase D (PKD) proteins bind phorbol esters and diacylglycerol and are closely related to PKCs (Valverde et al., Proc Natl Acad Sci USA Aug. 30, 1994;91(18):8572-6).

Protein kinase C plays a key role in modulating cellular responses in a wide variety of extracellular receptor-mediated signal transduction pathways, and in regulating cellular differentiation and proliferation in a wide variety of cells.

Protein kinase C genes/proteins may play an important role in many cancers, and therefore may be useful for drug development and for screening for, diagnosing, preventing, and/or treating a variety of cancers. For example, tumor-specific deletions have been identified within the gene for alpha-type protein kinase C in a melanoma cell line (Linnenbach et al., Proc Natl Acad Sci USA January 1988;85(1):74-8). Elevated expression levels of PKCs have been observed in certain tumor cell lines and it has been suggested that PKCs play an important role in signal transduction pathways related to growth control (Johannes et al., J Biol Chem Feb. 25, 1994;269(8):6140-8).

For a further review of PKCs, see Owczarek et al., Cytogenet. Cell Genet. 89: 240-241, 2000 and Hayashi et al., Biochim Biophys Acta May 6, 1999;1450(1):99-106.

Kinase proteins, particularly members of the protein kinase C subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of kinase proteins. The present invention advances the state of the art by providing previously unidentified human kinase proteins that have homology to members of the protein kinase C subfamily.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human kinase peptides and proteins that are related to the protein kinase C subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas.

DESCRIPTION OF THE FIGURE SHEETS

FIGS. 1A-1C provide the nucleotide sequence of a cDNA molecule that encodes the kinase protein of the present invention. (SEQ ID NO: 1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas.

FIGS. 2A-2F provide the predicted amino acid sequence of the kinase of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIGS. 3-1 to 3-33 provides genomic sequences that span the gene encoding the kinase protein of the present invention. (SEQ ID NO:3) In addition structure and finctional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As indicated in FIG. 3, SNPs were identified at 44 different nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a kinase protein or part of a kinase protein and are related to the protein kinase C subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human kinase peptides and proteins that are related to the protein kinase C subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these kinase peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the kinase of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known kinase proteins of the protein kinase C subfamily and the expression pattern observed. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known protein kinase C family or subfamily of kinase proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the kinase family of proteins and are related to the protein kinase C subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the kinase peptides of the present invention, kinase peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the kinase peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be “isolated” or “purified” when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, “substantially free of cellular material” includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language “substantially free of chemical precursors or other chemicals” includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the kinase peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated kinase peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. For example, a nucleic acid molecule encoding the kinase peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO: 1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the kinase peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The kinase peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric arid fusion proteins comprise a kinase peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the kinase peptide. “Operatively linked” indicates that the kinase peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the kinase peptide.

In some uses, the fusion protein does not affect the activity of the kinase peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant kinase peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A kinase peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the kinase peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the kinase peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., Nucleic Acids Res. 12(1):387 (1984)) (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a “query sequence” to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (J. Mol. Biol. 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the kinase peptides of the present invention as well as being encoded by the same genetic locus as the kinase peptide provided herein. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 19 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

Allelic variants of a kinase peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by the same genetic locus as the kinase peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 19 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase proteins of the present invention. SNPs were identified at 44 different nucleotide positions, including a non-synonymous coding SNP at position 42934. The change in the amino acid sequence that this SNP causes is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

Paralogs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide, as being encoded by a gene from humans, and as having similar activity or finction. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the kinase peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the kinase peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a kinase peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., Science 247:1306-1310 (1990).

Variant kinase peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., Science 244:1081-1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as kinase activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992); de Vos et al. Science 255:306-312 (1992)).

The present invention further provides fragments of the kinase peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a kinase peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the kinase peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the kinase peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in kinase peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as Proteins—Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al. (Meth. Enzymol. 182: 626-646 (1990)) and Rattan et al. (Ann. N Y Acad. Sci. 663:48-62 (1992)).

Accordingly, the kinase peptides of the present invention also encompass derivatives or analogs in which a substituted arnino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature kinase peptide is fused with another compound, such as a compound to increase the half-life of the kinase peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature kinase peptide, such as a leader or secretory sequence or a sequence for purification of the mature kinase peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a kinase-effector protein interaction or kinase-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, kinases isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the kinase. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas. A large percentage of pharmaceutical agents are being developed that modulate the activity of kinase proteins, particularly members of the protein kinase C subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to kinases that are related to members of the protein kinase C subfamily. Such assays involve any of the known kinase functions or activities or properties useful for diagnosis and treatment of kinase-related conditions that are specific for the subfamily of kinases that the one of the present invention belongs to, particularly in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the kinase, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the kinase protein.

The polypeptides can be used to identify compounds that modulate kinase activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the kinase. Both the kinases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the kinase. These compounds can be further screened against a functional kinase to determine the effect of the compound on the kinase activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the kinase to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the kinase protein and a molecule that normally interacts with the kinase protein, e.g. a substrate or a component of the signal pathway that the kinase protein normally interacts (for example, another kinase). Such assays typically include the steps of combining the kinase protein with a candidate compound under conditions that allow the kinase protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the kinase protein and the target, such as any of the associated effects of signal transduction such as protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′)₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant kinases or appropriate fragments containing mutations that affect kinase function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) kinase activity. The assays typically involve an assay of events in the signal transduction pathway that indicate kinase activity. Thus, the phosphorylation of a substrate, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the kinase protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the kinase can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the kinase can be assayed. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas.

Binding and/or activating compounds can also be screened by using chimeric kinase proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate then that which is recognized by the native kinase. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the kinase is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the kinase (e.g. binding partners and/or ligands). Thus, a compound is exposed to a kinase polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble kinase polypeptide is also added to the mixture. If the test compound interacts with the soluble kinase polypeptide, it decreases the amount of complex formed or activity from the kinase target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the kinase. Thus, the soluble polypeptide that competes with the target kinase region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the kinase protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigina Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of kinase-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a kinase-binding protein and a candidate compound are incubated in the kinase protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the kinase protein target molecule, or which are reactive with kinase protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the kinases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of kinase protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the kinase pathway, by treating cells or tissues that express the kinase. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. These methods of treatment include the steps of administering a modulator of kinase activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the kinase proteins can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the kinase and are involved in kinase activity. Such kinase-binding proteins are also likely to be involved in the propagation of signals by the kinase proteins or kinase targets as, for example, downstream elements of a kinase-mediated signaling pathway. Alternatively, such kinase-binding proteins are likely to be kinase inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a kinase protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a kinase-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the kinase protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a kinase-modulating agent, an antisense kinase nucleic acid molecule, a kinase-specific antibody, or a kinase-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The kinase proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. The method involves contacting a biological sample with a compound capable of interacting with the kinase protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered kinase activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (Clin. Exp. Pharmacol. Physiol. 23(10-11):983-985 (1996)), and Linder, M. W. (Clin. Chem. 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the kinase protein in which one or more of the kinase functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and kinase activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Accordingly, methods for treatment include the use of the kinase protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab′)₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the kinase proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or kinase/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidinlbiotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵s or ³H.

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas. Further, such antibodies can be used to detect protein in situ, in vitro, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the kinase peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nuleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a kinase peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the kinase peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an “isolated” nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5 KB, 4 KB, 3 KB, 2 KB, or 1 KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an “isolated” nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIGS. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIGS. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in FIGS. 1 or 3 (SEQ ID NO: 1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5′ and 3′ non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the kinase peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5′ and 3′ sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the kinase proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5′ to the ATG start site in the genomic sequence provided in FIG. 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 19 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase proteins of the present invention. SNPs were identified at 44 different nucleotide positions, including a non-synonymous coding SNP at position 42934. The change in the amino acid sequence that this SNP causes is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. As indicated in FIG. 3, SNPs, were identified at 44 different nucleotide positions.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5′ noncoding regions, the coding region, and 3′ noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 19 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data.

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in kinase protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA includes Southern hybridizations and in situ hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a kinase protein, such as by measuring a level of a kinase-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a kinase gene has been mutated. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate kinase nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the kinase gene, particularly biological and pathological processes that are mediated by the kinase in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. The method typically includes assaying the ability of the compound to modulate the expression of the kinase nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired kinase nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the kinase nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for kinase nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the kinase protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of kinase gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of kinase mRNA in the presence of the candidate compound is compared to the level of expression of kinase mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate kinase nucleic acid expression in cells and tissues that express the kinase. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for kinase nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the kinase nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1 indicates expression in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the kinase gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in kinase nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in kinase genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the kinase gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the kinase gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a kinase protein.

Individuals carrying mutations in the kinase gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase proteins of the present invention. SNPs were identified at 44 different nucleotide positions, including a non-synonymous coding SNP at position 42934. The change in the amino acid sequence that this SNP causes is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements. The gene encoding the novel kinase protein of the present invention is located on a genome component that has been mapped to human chromosome 19 (as indicated in FIG. 3), which is supported by multiple lines of evidence, such as STS and BAC map data. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., Science 241:1077-1080 (1988); and Nakazawa et al., PNAS 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al., Nucleic Acids Res. 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a kinase gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant kinase gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al., Adv. Chromatogr. 36:127-162 (1996); and Griffin et al., Appl. Biochem. Biotechnol. 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230:1242 (1985)); Cotton et al., PNAS 85:4397 (1988); Saleeba et al., Meth. Enzymol. 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al, PNAS 86:2766 (1989); Cotton et al., Mutat. Res. 285:125-144 (1993); and Hayashi et al., Genet. Anal. Tech. Appl. 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al., Nature 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the kinase gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase proteins of the present invention. SNPs were identified at 44 different nucleotide positions, including a non-synonymous coding SNP at position 42934. The change in the amino acid sequence that this SNP causes is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control kinase gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of kinase protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into kinase protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of kinase nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired kinase nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the kinase protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in kinase gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired kinase protein to treat the individual.

The invention also encompasses kits for detecting the presence of a kinase nucleic acid in a biological sample. Experimental data as provided in FIG. 1 indicates that kinase proteins of the present invention are expressed in humans in the lung (including fetal and carcinoid lung tissue), lymph (including mantle cell lymphomas of the lymph node), ovary tumors, kidney, colon, cervix, bone marrow, brain (including fetal), heart (including fetal), fetal liver, uterus, and pancreas. Specifically, a virtual northern blot shows expression in lung, carcinoid lung tissue, lymph, mantle cell lymphomas of the lymph node, ovary tumors, kidney, colon, and cervix. In addition, PCR-based tissue screening panels indicate expression in bone marrow, brain (including fetal), colon, heart (including fetal), kidney, lung (including fetal), fetal liver, uterus, and pancreas. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting kinase nucleic acid in a biological sample; means for determining the amount of kinase nucleic acid in the sample; and means for comparing the amount of kinase nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect kinase protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

As used herein “Arrays” or “Microarrays” refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5′, or 3′, sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5′ or at the 3′ end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The “pairs” will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the kinase proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the kinase gene of the present invention. FIG. 3 provides information on SNPs that have been found in the gene encoding the kinase proteins of the present invention. SNPs were identified at 44 different nucleotide positions, including a non-synonymous coding SNP at position 42934. The change in the amino acid sequence that this SNP causes is indicated in FIG. 3 and can readily be determined using the universal genetic code and the protein sequence provided in FIG. 2 as a reference. SNPs outside the ORF and in introns may affect control/regulatory elements.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (1 982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified kinase gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/Host Cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term “vector” refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ, the lac, TRP, and TAC promoters from E. Coli, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, E. coli, Streptomyces, and Salmonella typhimurium. Eukaryotic cells include, but are not limited to, yeast, insect cells such as Drosophila, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith et al., Gene 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., Gene 69:301-315 (1988)) and pET 11 d (Studier et al., Gene Expression Technology: Methods in Enzymology 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example E. coli. (Wada et al., Nucleic Acids Res. 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., S. cerevisiae include pYepSec1 (Baldari, et al., EMBO J. 6:229-234 (1987)), pMFa (Kurjan et al, Cell 30:933-943(1982)), pJRY88 (Schultz et al., Gene 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., Mol. Cell Biol. 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. Nature 329:840(1987)) and pMT2PC (Kaufinan et al., EMBO J. 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as kinases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with kinases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of Vectors and Host Cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a kinase protein or peptide that can be further purified to produce desired amounts of kinase protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the kinase protein or kinase protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native kinase protein is useful for assaying compounds that stimulate or inhibit kinase protein function.

Host cells are also useful for identifying kinase protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant kinase protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native kinase protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a kinase protein and identifying and evaluating modulators of kinase protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the kinase protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences usefil in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the kinase protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome andlor expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. PNAS 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of S. cerevisiae (O'Gorman et al. Science 251:1351-1355 (1991). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein is required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. Nature 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G_(o) phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could effect substrate binding, kinase protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo kinase protein function, including substrate interaction, the effect of specific mutant kinase proteins on kinase protein function and substrate interaction, and the effect of chimeric kinase proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more kinase protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

                   #             SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 4 <210> SEQ ID NO 1 <211> LENGTH: 2637 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 atggccaccg ccccctctta tcccgccggg ctccctggct ctcccgggcc gg #ggtctcct     60 ccgccccccg gcggcctaga gctgcagtcg ccgccaccgc tactgcccca ga #tcccggcc    120 ccgggttccg gggtctcctt tcacatccag atcgggctga cccgcgagtt cg #tgctgttg    180 cccgccgcct ccgagctggc tcatgtgaag cagctggcct gttccatcgt gg #accagaag    240 ttccctgagt gtggcttcta cggcctttac gacaagatcc tgcttttcaa ac #atgacccc    300 acgtcggcca acctcctgca gctggtgcgc tcgtccggag acatccagga gg #gcgacctg    360 gtggaggtgg tgctgtcggc ctcggccacc ttcgaggact tccagatccg cc #cgcacgcc    420 ctcacggtgc actcctatcg ggcgcctgcc ttctgtgatc actgcgggga ga #tgctcttc    480 ggcctagtgc gccagggcct caagtgcgat ggctgcgggc tgaactacca ca #agcgctgt    540 gccttcagca tccccaacaa ctgtagtggg gcccgcaaac ggcgcctgtc at #ccacgtct    600 ctggccagtg gccactcggt gcgcctcggc acctccgagt ccctgccctg ca #cggctgaa    660 gagctgagcc gtagcaccac cgaactcctg cctcgccgtc ccccgtcatc ct #cttcctcc    720 tcttctgcct catcgtatac gggccgcccc attgagctgg acaagatgct gc #tctccaag    780 gtcaaggtgc cgcacacctt cctcatccac agctatacac ggcccaccgt tt #gccaggct    840 tgcaagaaac tcctcaaggg cctcttccgg cagggcctgc aatgcaaaga ct #gcaagttt    900 aactgtcaca aacgctgcgc cacccgcgtc cctaatgact gcctggggga gg #cccttatc    960 aatggagatg tgccgatgga ggaggccacc gatttcagcg aggctgacaa ga #gcgccctc   1020 atggatgagt cagaggactc cggtgtcatc cctggctccc actcagagaa tg #cgctccac   1080 gccagtgagg aggaggaagg cgagggaggc aaggcccaga gctccctggg gt #acatcccc   1140 ctaatgaggg tggtgcaatc ggtgcgacac acgacgcgga aatccagcac ca #cgctgcgg   1200 gagggttggg tggttcatta cagcaacaag gacacgctga gaaagcggca ct #attggcgc   1260 ctggactgca agtgtatcac gctcttccag aacaacacga ccaacagata ct #ataaggaa   1320 attccgctgt cagaaatcct cacggtggag tccgcccaga acttcagcct tg #tgccgccg   1380 ggcaccaacc cacactgctt tgagatcgtc actgccaatg ccacctactt cg #tgggcgag   1440 atgcctggcg ggactccggg tgggccaagt gggcaggggg ctgaggccgc cc #ggggctgg   1500 gagacagcca tccgccaggc cctgatgccc gtcatccttc aggacgcacc ca #gcgcccca   1560 ggccacgcgc cccacagaca agcttctctg agcatctctg tgtccaacag tc #agatccaa   1620 gagaatgtgg acattgccac tgtctaccag atcttccctg acgaagtgct gg #gctcaggg   1680 cagtttggag tggtctatgg aggaaaacac cggaagacag gccgggacgt gg #cagttaag   1740 gtcattgaca aactgcgctt ccctaccaag caggagagcc agctccggaa tg #aagtggcc   1800 attctgcaga gcctgcggca tcccgggatc gtgaacctgg agtgcatgtt cg #agacgcct   1860 gagaaagtgt ttgtggtgat ggagaagctg catggggaca tgttggagat ga #tcctgtcc   1920 agtgagaagg gccggctgcc tgagcgcctc accaagttcc tcatcaccca ga #tcctggtg   1980 gctttgagac accttcactt caagaacatt gtccactgtg acttgaaacc ag #aaaacgtg   2040 ttgctggcat cagcagaccc atttcctcag gtgaagctgt gtgactttgg ct #ttgctcgc   2100 atcatcggcg agaagtcgtt ccgccgctca gtggtgggca cgccggccta cc #tggcaccc   2160 gaggtgctgc tcaaccaggg ctacaaccgc tcgctggaca tgtggtcagt gg #gcgtgatc   2220 atgtacgtca gcctcagcgg caccttccct ttcaacgagg atgaggacat ca #atgaccag   2280 atccagaacg ccgccttcat gtacccggcc agcccctgga gccacatctc ag #ctggagcc   2340 attgacctca tcaacaacct gctgcaggtg aagatgcgca aacgctacag cg #tggacaaa   2400 tctctcagcc acccctggtt acaggagtac cagacgtggc tggacctccg ag #agctggag   2460 gggaagatgg gagagcgata catcacgcat gagagtgacg acgcgcgctg gg #agcagttt   2520 gcagcagagc atccgctgcc tgggtctggg ctgcccacgg acagggatct cg #gtggggcc   2580 tgtccaccac aggaccacga catgcagggg ctggcggagc gcatcagtgt tc #tctga      2637 <210> SEQ ID NO 2 <211> LENGTH: 878 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 Met Ala Thr Ala Pro Ser Tyr Pro Ala Gly Le #u Pro Gly Ser Pro Gly  1               5   #                10   #                15 Pro Gly Ser Pro Pro Pro Pro Gly Gly Leu Gl #u Leu Gln Ser Pro Pro             20       #            25       #            30 Pro Leu Leu Pro Gln Ile Pro Ala Pro Gly Se #r Gly Val Ser Phe His         35           #        40           #        45 Ile Gln Ile Gly Leu Thr Arg Glu Phe Val Le #u Leu Pro Ala Ala Ser     50               #    55               #    60 Glu Leu Ala His Val Lys Gln Leu Ala Cys Se #r Ile Val Asp Gln Lys 65                   #70                   #75                   #80 Phe Pro Glu Cys Gly Phe Tyr Gly Leu Tyr As #p Lys Ile Leu Leu Phe                 85   #                90   #                95 Lys His Asp Pro Thr Ser Ala Asn Leu Leu Gl #n Leu Val Arg Ser Ser             100       #           105       #           110 Gly Asp Ile Gln Glu Gly Asp Leu Val Glu Va #l Val Leu Ser Ala Ser         115           #       120           #       125 Ala Thr Phe Glu Asp Phe Gln Ile Arg Pro Hi #s Ala Leu Thr Val His     130               #   135               #   140 Ser Tyr Arg Ala Pro Ala Phe Cys Asp His Cy #s Gly Glu Met Leu Phe 145                 1 #50                 1 #55                 1 #60 Gly Leu Val Arg Gln Gly Leu Lys Cys Asp Gl #y Cys Gly Leu Asn Tyr                 165   #               170   #               175 His Lys Arg Cys Ala Phe Ser Ile Pro Asn As #n Cys Ser Gly Ala Arg             180       #           185       #           190 Lys Arg Arg Leu Ser Ser Thr Ser Leu Ala Se #r Gly His Ser Val Arg         195           #       200           #       205 Leu Gly Thr Ser Glu Ser Leu Pro Cys Thr Al #a Glu Glu Leu Ser Arg     210               #   215               #   220 Ser Thr Thr Glu Leu Leu Pro Arg Arg Pro Pr #o Ser Ser Ser Ser Ser 225                 2 #30                 2 #35                 2 #40 Ser Ser Ala Ser Ser Tyr Thr Gly Arg Pro Il #e Glu Leu Asp Lys Met                 245   #               250   #               255 Leu Leu Ser Lys Val Lys Val Pro His Thr Ph #e Leu Ile His Ser Tyr             260       #           265       #           270 Thr Arg Pro Thr Val Cys Gln Ala Cys Lys Ly #s Leu Leu Lys Gly Leu         275           #       280           #       285 Phe Arg Gln Gly Leu Gln Cys Lys Asp Cys Ly #s Phe Asn Cys His Lys     290               #   295               #   300 Arg Cys Ala Thr Arg Val Pro Asn Asp Cys Le #u Gly Glu Ala Leu Ile 305                 3 #10                 3 #15                 3 #20 Asn Gly Asp Val Pro Met Glu Glu Ala Thr As #p Phe Ser Glu Ala Asp                 325   #               330   #               335 Lys Ser Ala Leu Met Asp Glu Ser Glu Asp Se #r Gly Val Ile Pro Gly             340       #           345       #           350 Ser His Ser Glu Asn Ala Leu His Ala Ser Gl #u Glu Glu Glu Gly Glu         355           #       360           #       365 Gly Gly Lys Ala Gln Ser Ser Leu Gly Tyr Il #e Pro Leu Met Arg Val     370               #   375               #   380 Val Gln Ser Val Arg His Thr Thr Arg Lys Se #r Ser Thr Thr Leu Arg 385                 3 #90                 3 #95                 4 #00 Glu Gly Trp Val Val His Tyr Ser Asn Lys As #p Thr Leu Arg Lys Arg                 405   #               410   #               415 His Tyr Trp Arg Leu Asp Cys Lys Cys Ile Th #r Leu Phe Gln Asn Asn             420       #           425       #           430 Thr Thr Asn Arg Tyr Tyr Lys Glu Ile Pro Le #u Ser Glu Ile Leu Thr         435           #       440           #       445 Val Glu Ser Ala Gln Asn Phe Ser Leu Val Pr #o Pro Gly Thr Asn Pro     450               #   455               #   460 His Cys Phe Glu Ile Val Thr Ala Asn Ala Th #r Tyr Phe Val Gly Glu 465                 4 #70                 4 #75                 4 #80 Met Pro Gly Gly Thr Pro Gly Gly Pro Ser Gl #y Gln Gly Ala Glu Ala                 485   #               490   #               495 Ala Arg Gly Trp Glu Thr Ala Ile Arg Gln Al #a Leu Met Pro Val Ile             500       #           505       #           510 Leu Gln Asp Ala Pro Ser Ala Pro Gly His Al #a Pro His Arg Gln Ala         515           #       520           #       525 Ser Leu Ser Ile Ser Val Ser Asn Ser Gln Il #e Gln Glu Asn Val Asp     530               #   535               #   540 Ile Ala Thr Val Tyr Gln Ile Phe Pro Asp Gl #u Val Leu Gly Ser Gly 545                 5 #50                 5 #55                 5 #60 Gln Phe Gly Val Val Tyr Gly Gly Lys His Ar #g Lys Thr Gly Arg Asp                 565   #               570   #               575 Val Ala Val Lys Val Ile Asp Lys Leu Arg Ph #e Pro Thr Lys Gln Glu             580       #           585       #           590 Ser Gln Leu Arg Asn Glu Val Ala Ile Leu Gl #n Ser Leu Arg His Pro         595           #       600           #       605 Gly Ile Val Asn Leu Glu Cys Met Phe Glu Th #r Pro Glu Lys Val Phe     610               #   615               #   620 Val Val Met Glu Lys Leu His Gly Asp Met Le #u Glu Met Ile Leu Ser 625                 6 #30                 6 #35                 6 #40 Ser Glu Lys Gly Arg Leu Pro Glu Arg Leu Th #r Lys Phe Leu Ile Thr                 645   #               650   #               655 Gln Ile Leu Val Ala Leu Arg His Leu His Ph #e Lys Asn Ile Val His             660       #           665       #           670 Cys Asp Leu Lys Pro Glu Asn Val Leu Leu Al #a Ser Ala Asp Pro Phe         675           #       680           #       685 Pro Gln Val Lys Leu Cys Asp Phe Gly Phe Al #a Arg Ile Ile Gly Glu     690               #   695               #   700 Lys Ser Phe Arg Arg Ser Val Val Gly Thr Pr #o Ala Tyr Leu Ala Pro 705                 7 #10                 7 #15                 7 #20 Glu Val Leu Leu Asn Gln Gly Tyr Asn Arg Se #r Leu Asp Met Trp Ser                 725   #               730   #               735 Val Gly Val Ile Met Tyr Val Ser Leu Ser Gl #y Thr Phe Pro Phe Asn             740       #           745       #           750 Glu Asp Glu Asp Ile Asn Asp Gln Ile Gln As #n Ala Ala Phe Met Tyr         755           #       760           #       765 Pro Ala Ser Pro Trp Ser His Ile Ser Ala Gl #y Ala Ile Asp Leu Ile     770               #   775               #   780 Asn Asn Leu Leu Gln Val Lys Met Arg Lys Ar #g Tyr Ser Val Asp Lys 785                 7 #90                 7 #95                 8 #00 Ser Leu Ser His Pro Trp Leu Gln Glu Tyr Gl #n Thr Trp Leu Asp Leu                 805   #               810   #               815 Arg Glu Leu Glu Gly Lys Met Gly Glu Arg Ty #r Ile Thr His Glu Ser             820       #           825       #           830 Asp Asp Ala Arg Trp Glu Gln Phe Ala Ala Gl #u His Pro Leu Pro Gly         835           #       840           #       845 Ser Gly Leu Pro Thr Asp Arg Asp Leu Gly Gl #y Ala Cys Pro Pro Gln     850               #   855               #   860 Asp His Asp Met Gln Gly Leu Ala Glu Arg Il #e Ser Val Leu 865                 8 #70                 8 #75 <210> SEQ ID NO 3 <211> LENGTH: 43950 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 3 cgcggcgggg agggcagggg tgacgctcgg agaacagaga ggccgaaccc ag #agagcggg     60 ccgggacctg ataccgattt cccacccgtc ccctgccatg ggcgccggac gc #ctgccgga    120 gagggctccc ctccttaaag ggccagtggc ctccaagccc gacgcctgcg ac #cggcggtg    180 ggtgatagtg tttcccctcc ctgtccagcc gagggaaaag ttaactttcc ag #gcttggct    240 gtgttcaggg aaggaactgg tctcgcctgc ctgccctcca tccctcacac ca #tcccttgt    300 cccggaccct ggaggcggag gtccagcccc caactcggag gccccgggcc ca #ccctcccc    360 ttccgccccc ggcccctcgg caggctccgc ccctctctga cgtcgccgag gc #ccgcgccg    420 attggtcgac tgcactgtcg ctccggacac ttcctcctgg gccgccgccg cc #gccgccga    480 cttaaacttt ggagggggaa aaagagctac tggcgcctgg cgaccctccc tg #ccccccac    540 ccaaccccgc tccggcaacg cccccttcct cacggctccc gaccgaactt tt #ctccaact    600 tctgcgactc gtgagattcc cttctaccca ctccggccct cgggacccct ct #gcccatcc    660 cctggccggt cgggtccctg cgaacccctt tatctctgga atccactcgg tc #cccgactc    720 agagactcct gccctccacc cccaaggtga attcccccgg gccgccttct ga #gtgggatc    780 ctcttcttgg agcactggat cctgggattc cctctgcccc cttctcaatc cc #tcctctag    840 ggaaggggcc tttgaatcgc gggctctcct gatccctgtg accccgacct ac #tagatttc    900 ctctcaggct tcttggaatc tcaatcgctg ggacctccaa cccactactt tt #ctcctttc    960 tgatcttctg ggagccctgg attccgggcc tctgacccac tatagtgcct tt #ctctcctt   1020 cccaggaccc cgccatcctc aggtcccctc cgcctgccag atcttttctc gg #atccccgc   1080 tctcccacca cctgctcacg agatcccgcg gatctagaac ccagggtccc cc #ggggcccc   1140 ccggccgggt cccgggtggg ctccaggcgg ccggtccccg gcctcccccc at #ggccaccg   1200 ccccctctta tcccgccggg ctccctggct ctcccgggcc ggggtctcct cc #gccccccg   1260 gcggcctaga gctgcagtcg ccgccaccgc tactgcccca gatcccggcc cc #gggttccg   1320 gggtctcctt tcacatccag atcgggctga cccgcgagtt cgtgctgttg cc #cgccgcct   1380 ccgagctggc tcatgtgaag cagctggcct gttccatcgt ggaccagaag gt #gagggcgc   1440 aggctccctg gatccagctc ggggagaggt tgaaggaggg ggcgctggca ga #ggggtctg   1500 gggcctggtg tgcggaagag ggaggaagga gacctgagct ttgggtgatg ga #gggatagg   1560 gggcattgcc ccccttccat tgcccctctc cccaccatcc ctttgagaga gg #actgggca   1620 ggggtggggt gccccagagg cctccccaaa tttcatgtcc ctgcatgtcg tt #gttttctg   1680 cagcaaacag ggaggaaggg aggggccagc caggtgtaga gaggggagga ag #gggcagca   1740 gatgtcggcg gacctccacg tccaggccca tcccgggcct cccatttggt gg #aaacagga   1800 gaaattgaac ccgggctggc catggtgatc cggtgacatg tgtgggtgca gg #tgcttgag   1860 ttagctgcca ggggcaagtg aggtctcgga gcccaattct gccctcccct aa #gcctgaga   1920 tatgtgtgga ggggcaggca ctcctacaga ccctggggac tctattccct tt #cctagtca   1980 cagtgctgtt agcctactct taattttgga caccagggtc cccagggtgg gc #agctgggt   2040 gttatggcaa gaggaaacca ggtggaactc cacgtctaaa ccgtgaaatg tt #aaaagaat   2100 agtgggcttc tgtgttggag tactggactg tagaaatgtt agaatattag aa #tcataact   2160 tgttggaata tgcatcctag gcaattaaat tgcccccatg ttcgtgttca aa #tattagaa   2220 ttctaggttt gtgaaatagt aaaacattaa aatgctggaa tattagattc ct #agattgtt   2280 gaatcctaga aagttaaaat gttagaattt tagaatgctg gatggatgag gt #ccttgaat   2340 gctaaagaat tcaaagagca cagtcctagc ttgtcagact cctagaatat ta #aaatatta   2400 gattaccgct tatttaggtt attgaaatcc taaaatgtat agtgatacca gg #taggaatc   2460 tagaatgtat aattctataa tgtgagcatg ttggagtccc aaaatatcca aa #ttccagaa   2520 tcttttcaga ctcctggaaa tgaatccttt gggcatcaga gaaacgtggg ga #actgggcc   2580 agctccccca ttctacagac aaggaaactg aagcttagag aaaaacttcc ca #aggggtca   2640 gggccaaggc agtcctggtc ttctgtggac tctctcttag cagtgagaac tg #atagggtt   2700 ttgcccacca aatgcctaaa tcccgcaggc ccagctcacc accccaactc ag #cccacttc   2760 atgggaagct ggtggcagtg ggggtacggg ggcagattgt cccttgggtg aa #cttctttg   2820 tccagtgctc aagtccccag cctgccccgc tcaggcttca ccccagtttt at #ttttctgc   2880 caggtccagg tgtgttaggg ccgcgtacct tccttcccga ggccccaccg gg #gcagtttc   2940 actttctgtt ctactaggtt tcatttcctg cccccaggcc cccaaagctg ag #gacccaga   3000 cacctgggtc ctttgagcat tgggtggcag gcgccctcct tatctccagc gc #cctcgagt   3060 ccaagtcccc cggccccccc cccccacttt cccaggagcc ccgaaaagtc ct #ccttccag   3120 ctcgccccac cccagtgctg ggcctggagc caggtaactg ggacaacaat ag #acagatcc   3180 aggaaggaag ctggggggcg ggtgtgtgag cctggggagg aggcacaggg ga #gggagtgt   3240 tcattcagca tcccctccca cctccgccag gttccggaaa attcgaggtg tc #cacgctcc   3300 cggagccact ctccctccca ccccagctcc cccttccagc caccaaaccc ac #gccggcgc   3360 cccctccccg tacaattggg gcgctggcat cctgcccggc tcgcgctggg gt #tgggaggg   3420 ggcaggcagg aagcgagggc ctgcggggtc tctgcgtttc cgggggaaac ag #ccggccct   3480 gccctgggag ggtcacagtc cgcccgctgc tgaaggcggc tctgagcttt tc #cgtcgcca   3540 catccctctc ccgcccctca gttccctgag tgtggcttct acggccttta cg #acaagatc   3600 ctgcttttca aacatgaccc cacgtcggcc aacctcctgc agctggtgcg ct #cgtccgga   3660 gacatccagg agggcgacct ggtggaggtg gtgctgtcgg gtgagaggtg gt #ggccggcc   3720 tgggggcggg gcctcgggtg ggggcggggc atctggggga ggagagggta gg #gggagtta   3780 gaagtcagga gaggccgggt gtagtggctc acgcctgtga tcccagcact tt #gggaggct   3840 gagctggagc tggggggatc gcttgagccc aggagttcga gatcagcctg gg #caacatag   3900 tgagattcca tctctacccc tttctctccc tctgaaaaaa aaaaataagg ag #agttgggg   3960 gcttctggaa gatggttaca gagtggggtc atgaaggcgc tctttaggga ct #ggtctaaa   4020 ctttcattta tggattagga tgctagtgac acgctttgta cagtttgaaa at #tcattgag   4080 ctgtgcactt gtgatgtgcg gcctttcctg aacatatgtt atacttattt at #ttataaaa   4140 ctagtcaagt gcagtagtta gaagggggaa aagaggagaa gaaggagttg ga #tctgtaac   4200 tgactgtgtt atgcttaaat ataaaggtaa aaaatgggcc agctgcagtg gc #tcacacct   4260 gtaatcccag cagtttggga ggctgaggtg ggaggatcgc tggagcccag ga #gtttgaga   4320 ccagcctggg caacataagg agaccccatc tcttaaaaaa aaaaaaaaaa aa #aaaagtta   4380 accgggcgag gtggcacacg tctgtagtct cagctacttg ggaggctgag gt #gggaggat   4440 ttcttgagct taggagtttg aggctgcagt gagccacgat catgtcactg ca #ctccagcc   4500 tgggcaacag agagagaccc tatctctaaa aaagaaaaaa agtagaaaaa ga #aaaaaaaa   4560 agttatgatg tccatggctc ctgccacgaa aatgctaaat taaatcagaa tc #tctgcaaa   4620 gtgagatgga atctgcacat cagtattttt aaaagccccc aggtgatttt ct #aagacaca   4680 gccagaagcc agttcatcca ctcactattc cagtagtata gatgggcatg ct #ctcagcac   4740 cttagagcag tctatggccc ttggtccctc ttgagggtgg gggcagctgc ct #ttttcatg   4800 gctgtcttcc ctgctgctcc ggcatactgc agtgcccagt gaaaccggct ca #atgaatga   4860 atgacagaag tctggattta cacctttagt gaccttgttc aggctttaag ta #ctctttca   4920 tatcataagc tggcctcact tgaattttta tcttcattgt tgtctctccc ct #aaacctga   4980 gttttgtttt gtttttgtca tttttattat tttttgtttt tttagacgga gt #ctcgctct   5040 gtcacccagg ctggagtgca gtggcgcaaa ctcagcttgc tgcaacctct gc #ctcctggg   5100 ttcaagcgat tctcctgcct cagcctcccg agtagctggg attacaggcg cc #tgctacca   5160 cacgtggcta atttttgtat ttttagtaga gacgggattt caccttgttg gc #caggctgg   5220 tctcgaactg ctgatcttaa gtgatctgcc cacctcagcc tcccaaagtg ct #gcgattac   5280 aggtgtgagc caccgctccc ggccctgtta ttttgttttg aggcagggtc tt #gttctgtc   5340 acccaggctg gaatgcagtg gcatgaccac cactcactgc agcctctacc tc #ccagactg   5400 aagcaatcat cccgcctcag cctcctgagg tggctggact ataggcatta ca #ggcatgca   5460 ccaccacact gggctttttt tttttttctt ttttttagac agaatcttac tc #tgtcaccc   5520 aggctggagt gccgtggcat gatcttggct cacggcaacc tctgcctccc gg #gttcaagc   5580 aattctcctg cctcagcctc ctgagtagct gggattacag gcacgcggca cc #aggcctgg   5640 ctaatttttg tatttttagt agagacgggg tttcatcatg ttggccaggc tg #gtttcgaa   5700 cttctgacct caagtgatcc gcccacctgg gcctcccaaa gtgctgggat ta #cagatgtg   5760 agccaccggg caccgcctat ccatgttctt ttttgttgtt ggtggtggta tt #tttaatta   5820 aaaatttttt aatttggtaa aatatacata acataaaaat tactatttta gg #ccgggtgc   5880 agtggctcac gcctgtaatc ccaacacttt gagagaccga ggcgggcaga tc #acctgagt   5940 cgggagtttg agaccatccc tggccaacat ggtgaaactc cgtctctact aa #aaatacaa   6000 aaattagtcg ggtgtggtgg cgcatgcctg taatcccagc tactctggag gc #tgaggcag   6060 gagaactgct tgaacccggg aggcggactt gtggtgagcc gagatctcac ta #ctgtactc   6120 cagcctgggt gacagagtga aactctctaa caaacacaaa caaaaaagcc ca #caacattt   6180 taagcacttt taagcgtaca gttcagtaat ttaaagttca cgcacactgt tg #tgcagccg   6240 gtctccagaa ctgttgtcat cttgcgaaac tgaagctcct tgcccgttaa ac #aactcccc   6300 aattcccgct ctgtccctgc ccagggcgta gggatatatg tgttttgttc ag #gggtggag   6360 ctgggatttg aacccaggca gaatgtagta tgagagcaaa tgaaggaagg aa #ggaaagat   6420 cacaccttgc ggctgggagc actgtgagaa atcagggaac gtggggtctg ga #aaagcttt   6480 ggcctacccc gcctcaagca tccaccccta ttttccgcct acagcctcgg cc #accttcga   6540 ggacttccag atccgcccgc acgccctcac ggtgcactcc tatcgggcgc ct #gccttctg   6600 tgatcactgc ggggagatgc tcttcggcct agtgcgccag ggcctcaagt gc #gatggtga   6660 gagctaaagg gttgggggcg gggcctgggg cggggctctg caccgggggc gg #agcgtaat   6720 ggtcctggca cggggacagc gtggggagga ggagcgggtc tcagagctgg gg #gcgcagcc   6780 taggaagtaa taatgggaag aaggatgggc ccagaagcag agcttgggga ag #gagtggtg   6840 gggctgggcc ggggctcagg tctaggggcg gagcctagga ggtggagctg gg #agggacaa   6900 gtaggggctt aagaacagag cctaggggag cagaagggtg gcgggggaag ag #ggtggggc   6960 ctctatcagt tagggatcaa gcagagaaac atccaggagg agatatatat tg #agatattt   7020 atatgcaagg aatcagctta cagaattgtg tgggctggct aggcaactca aa #tctggctg   7080 ggcacagtgg gggaggccag taatcccagc actttgggag gcaaaggtag gt #ggatcact   7140 tgaggccagg agttcaagac cagcctgggc aacatagcaa gactctgcct gt #acaaaaaa   7200 taattagcca agcatggtga cagacacttg tggtcccagc cacttgggag gc #tgaggcgg   7260 gaggatcact tgagcctggg agctcgacac tgtagtgagc cctgattgca cc #actgcaca   7320 ccagcctggg tgacagagcg agaccctggc tcaaaaacag gaaaaaggcc gg #acacggtg   7380 gctcatgcct gtaatcccag cactttggga ggccgaggcg ggtggatcac ga #ggtcagga   7440 gattgagacc ctccctggct aacatggtga aaccccgtct ctactaaaaa ta #caaaaaat   7500 tagccggacg tggtggcaca cgcctgtagt cccagctact tgggaggctg ag #gcaggaga   7560 attgcttgga cctgagagga ggaggttgca gtgagccgag attgtgccac tg #cactccag   7620 cctggtgata gagtgagact ccttctgaaa acagaaacaa aaacaaaaca at #aaaaagaa   7680 aaagaaaaaa aaatccatcc tatcaggaag ggcaagtggg aactcaggca ca #agctgaag   7740 ctgatgtcca caggtggaat ttcttcatcc gaaaagtctc tgatctgctt tt #taaaacat   7800 tcagctgatt gaatgagacc cacctagaac aagcaggatc acctctccca ct #tacagtca   7860 gctgattatg gattttcatc acatccagaa aatacctcca ctgggccggg tg #cggtggct   7920 cacgcctgta atcccagcac tctgggaggc cgaggcaggt gaatcacctg ag #gtcaggag   7980 ttcgagacca gcctgtccaa catggtgaaa ccccgtctct actaaaaata ca #aaaaagcc   8040 ggcgtgttgg tggacgcctg taattccagc tactcgggag gctcagtcag ga #gaatctct   8100 tgaacccggg aggcagagct tgcagtgagc tgagattgca ccattacact cc #agcctggg   8160 caacaagagc aaaactctgt ctcaaaaaaa tgaaaagaaa agaaaatacc tc #catggggc   8220 cttctctccc cagttcttcc tggagtcggg gaaaagctgg gttgagaagg tg #aaaagaaa   8280 aaacaaacct tgactgggca cagtggttca cacctgtaac cccagcactt tg #gaggctga   8340 ggcaggcgga tcatgaggtc aagagattga gaccaccctg gccaacatgg tg #aaacccca   8400 tctctcctaa aaatacaaaa attagcgggc gtggtggcat gtgcctatag tc #ccagctac   8460 ttgggaggct gaggtaggag aatcacttga acccaggaga cagaggttgc ag #tgagccga   8520 gatcgtgcca ctgcactcca gcctggcaac agagcgagac tccgtctcaa aa #aaaaaaaa   8580 acaaaaaaaa aaaacacaaa caaaccaacc ttcatggcaa catctagatt ag #tgtctgaa   8640 taactgtgga tctcgcctag ccaagctgac acattaacat gactatcagg gt #ccatctct   8700 tgtcaacctg gcacctgtct tagtttgtca gggctgcctt aacaaaatac ca #ccctgcgt   8760 ggcttaaatg acagacattt acttctcaaa atccctggaa ttgtgagagg ct #ggaaagac   8820 aaagatccag attctggcag ggttctgttt ctggtgtagc ctgctttcct gc #cttgcaga   8880 gggccatcat ttcactgtgc gctcacatgg gacacggaga gagagatccc tg #gtatctct   8940 tccctttata aggaaggcca ggcatggtgg ctcatgccta taatcccagc ac #tttgggag   9000 gatggtggat cgcttgagtc caggagttcg agaccagcat gggcgacatg gt #gaaacccc   9060 gtctctaaaa aatacaacaa attggccagg catggtggtg catacctcta gt #cctagcta   9120 ctcaagaggc tgaggtggga ggatcacctg ggcctgggag gttgaggctg cg #gtgagccg   9180 tgatcatgcc actgcactcc agcctaggtg acagaacacg attgtctcag ga #aaaaaaaa   9240 aaaaaaaaaa aaaaaagggt caccagtccc attggattac agccacactc tt #tcggcctc   9300 aattaacctt aattacctcc ataaaggcac cgtctccaga tatagttgca tt #ggaggtta   9360 gggtttcaac ataagaattt tgggggagac acagacattt agtccataac ag #cacccata   9420 catatctcct taaatcatag tttaaaaata tacaggtttt cttttttgga ga #cagcgtct   9480 cagtctgtca cccaggctgg agtgcagtgg cgcgatctca gctcaccaca ac #ctccactt   9540 cccaggctca agcgattctc ctgcctcagc ctaccgagta gctgggatta ca #ggcacaca   9600 ccattactgc ccggctaatt tttgtatttc tagtagagac ggggtttcac ca #cgttggcc   9660 aggctggtct tgaactcctg acctcaaatg atccacccgc cttgccctcc ca #cagtgctg   9720 ggattacagg catgagccac cgcgcctgtc caaaacatac agttctttaa gc #caagatgt   9780 ctcaaggttc agcccaagtg tcaagatcta tataggtcct ctgtccctgt ta #ttcatgct   9840 tctgagtgag aatgttgaaa tcggggctct gcctacagat gaaggccatg ta #cctgcatt   9900 ggctatgagg acagatgaca ggtgaggacc atccattctg tgatgagacc ct #gtggctcc   9960 atttttttgt gtgtgtgaga cagagtcttg ctccgtcacc caggatggag tg #cagtggcg  10020 tggtcttggc tcactgcaac ctctacctcc tgggttcaag caattctcct gc #ttcagcct  10080 cccaaatagc tgggattaca ggtgcgcacc accactcctg gctaattttt gt #atttttag  10140 tagacggggt ttcaccatgt tggccaggct ggtttcaagt aatccaccct cc #tcagcctc  10200 cccaagtgct gggattacag acatgagcca ctgcgctggg ccccatgcgc ct #ccattttt  10260 gtatggtgtg ccctgcaatt agagccatat tcttggatgt tccattgggt at #taggtctg  10320 agacagcatc tctagctccg tgggtgccac gcttgtacag aaatcctgat tc #tgggccag  10380 gcacggtggc tcacacctgt aatcccagca ctttgggagg ccaaggcggg cg #gatcatga  10440 ggtcaggagt tagagaccag cctggccaac atggtgaaac cctgtctcta ct #aaaactag  10500 aaaaattagc tgggtgtggt ggcgggtacc tataatccca gctactcggg ag #gctgaggc  10560 aggagaatca tttgaacctg agggggtgga ggttgcagtg agccgagatc at #accattgc  10620 actccagcct gggtgacagg gtgagactcc gtctcaaaaa aaaaaaaaaa aa #agaaatcc  10680 agtttctcca atatcctgtg ttccagatca tcatgcagtc caaagtatac tt #gtattatt  10740 taaggactct aggcctgcag atactgattc agtgcattaa aagctcttat aa #atattgcc  10800 atcgtccaca caccatatcc aactcttgag gtctcagcat atgcagtctt tg #tcatgata  10860 cagccctggt gtcatcaagt cctaatgggt tatcagcaca gacttcactg gt #gcagcatc  10920 acagatgatg gtcccagttc ctatggtggc aagagaaccc caaatgacta ca #ttccgaca  10980 ggagtttaac tctatcctga gactcattct gagagttata gataagattc tg #aaattctg  11040 gaaggcacat gagtgattca aggccaacac tgggaaatgg ttcctgtgtg ca #aagaccat  11100 ttgccctgct gaagctcttc ttgcagggcc aacaccgttc tccaagcttg cc #tccgtgat  11160 tacagcatgc agccaagaca gtgcctacaa tgaggaggtg tggaactgga aa #gcctggag  11220 caggcgggta ccagaagggc tcccaaaggc tggaggaaca ttcttcactc ca #gaatagaa  11280 agcgatcctg gaatcgtttg gaatcactgg agatgtatta gagcacacat ac #agaacgtc  11340 cagtgggaaa cagggagttg agctgatttc tccatggatg aggattttaa aa #gataaaat  11400 aggcagggca cagtggctca tgcctgtaat cccaacactt tgggaggctg ag #gtgggagg  11460 atcacttgag cccaggagtt caagaccagc ctgggcaatg tagcgagacc cc #atctctac  11520 aaaaaaataa aaataaaaaa attatctggg catggtagtg tatgtctgtg gt #tctggcta  11580 ctcaggaggc tgaggcagga ggattacttg agcccaggag ttgaaggctg ca #gtgagcta  11640 tgattgtgcc attgtgcttc agccgggggt acagggagat cctgtctcta ca #aaataaaa  11700 taagacaata agaagtcata cttctgccta gtatggtaca atggacctga gt #acaactga  11760 gaactctttt tttttttttg aaactgagtc tcgctgtatt gcccaggctg ga #gtgcagtg  11820 gcgtgatctc agctcactac aacctctgcc tcctgggttc aagtgattct cc #tgcctcag  11880 cctccggagt agctgggatt acaggcgtgt gccactacac ccggctaatt tt #gtattttt  11940 agtagagatg gggttttgcc atgttggcca gtgtggtctc aaactcctga cc #tcaagtga  12000 tccgccggcc ttggcctccc aaagtgctgg gattacaggc gtgagccacc at #gcgtggcc  12060 cacactacta agatttaatc acactactta gggattgcct ggattccagg tc #tacagaaa  12120 agagaaagtg gggtacaggg ggtgagcaga cctggaggga tagtgacctt ag #gggtgggg  12180 gtgaggagag gcattttctt ttggaaagtt ggggttgggg aaagaggggg aa #ccaaaggg  12240 gcctcagaaa aaggaaggtc agggttagaa gggggaacag gtgtctctag gg #agatggac  12300 aggagttttg gggaggacta gaaggaggtg cttaccatag aggactgggg ct #gggtcaga  12360 gctttggcgg ggacttttga ggcatccatt gttgcagtgg gaaaaggtgg gg #tgtgaggc  12420 gcgttcaggg cctggggggc agatggggtg atgtcggggc tacaagctgg aa #ctaggggt  12480 ggagctttgg agggaacctt tgaggtatcc cttgttggag tgggaaaatt tt #gggtgtga  12540 ggcgtgttca gggtctgggg gacagatggg gtgatggcag ggctacaagc tg #aaactggg  12600 gacagagctt tggggggagc ctttgaggtg acccttgttg gagtgagaaa ag #gggtgtgg  12660 gtgtgttcag ggtctggggg acagatgggg tgatggtggg gctacaagct gg #aacttggg  12720 gcagaactct aaggaggggt gggcctgaag gggctgatac acttacggat ag #tagtgcct  12780 tttggaggag atcgtgctgg cggggggtga tgggacagga ccaggtgaga ga #ttgggtgg  12840 aaagggcaca acttctcaag aagagaccta ggaggggcag acgccatgtc tc #ttactctc  12900 tggcgccccc tgcaggctgc gggctgaact accacaagcg ctgtgccttc ag #catcccca  12960 acaactgtag tggggcccgc aaacggcgcc tgtcatccac gtctctggcc ag #tggccact  13020 cggtgcgcct cggcacctcc gagtccctgc cctgcacggc tgaagagctg gt #gaggagat  13080 gggggatggg acgggttggt ggctaggggg gtgacttggc ccaggcatgg gg #ccaacgca  13140 ctgatgtgtc ccctccattc ttgccaatga cagagccgta gcaccaccga ac #tcctgcct  13200 cgccgtcccc cgtcatcctc ttcctcctct tctgcctcat cgtatacggg cc #gccccatt  13260 gagctggaca agatgctgct ctccaaggtc aaggtgccgc acaccttcct ca #tccacagc  13320 tatacacggc ccaccgtttg ccaggcttgc aagaaactcc tcaagggcct ct #tccggcag  13380 ggcctgcaat gcaaaggtta gctgggcctg tcggggagga cagtacaggg tc #agaacctc  13440 cttcccgccc caacctggtc ttgtggcagg acacaaggat ctgagccttg gg #accccagg  13500 gcctcagaag gggagggccc tgaatcctag tgttctggga cctttggaat tc #tggaatct  13560 tagaacctca gttgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgttgt gt #tgtttttt  13620 gaagacaggg tgtcactcta tcacccaggc tggagtgcag tggcgcaatc ac #ggctcact  13680 gcagcttcaa cctcttgggt tcaagtgatc ctcctgcctc agcctcccaa gt #agctagga  13740 ctacaggtgg tgccaccaca cccagctaat tttcttttct tttttttttt tt #tgagacgg  13800 agtctcactc tgtcgcccag gctggagtgc agtggtgtga tctcgggctc ac #tgcaaact  13860 ctgcctcctg ggatcaggac attctcctgc ctcagcctcc tgagtagctg gg #actacagg  13920 cgcccgccac catgcctggc taattttttt gtatttttag tagagacggg gt #ttcaccat  13980 gttagctagg atggtctcga tctcctgacc ttgtgatcca cctgcctcga cc #tcccaaaa  14040 tgccgggatt acaggcgtga gccaccgcgc ctggccacac ccagctaatt tt #taaatcat  14100 ttgtagagag aaggtatcac tatattgttc aggctggtct tgaactcctg gg #ctcaagca  14160 atcctcctac ctcggcctcc caaagtgctg ggattacagg tgtgagccac cg #cgcccagc  14220 tgaacctcag tctttagaac cttggaatcc tagattcata acgtgcttag ca #tggaattc  14280 taaaactgta gaacctgaga attctagaat cagaaccata gcattcaaga at #tccgaatg  14340 atagaattca gctaaaataa caacagaact ttagattaca catcttagat ct #cccaagtt  14400 atagactctc agagcatgag aattttggaa ccatgggatt tgagggtaat ag #aaacatag  14460 gcacatcaaa tttgagagtc ttagacgtct agaatcatat aagcttgaaa cc #atcgtaac  14520 ctagaatcct ggaaattcta gactcccaga actttgaaca atcaaattct ag #aatccagc  14580 caggtgtggt ggctcatgca tgtaatctca gcactttggg aggccaaggt ag #gtggatca  14640 cttgagccta ggagtttaag accagcctgg gcaacatggt gaaaccctgt ct #ctacaaaa  14700 aaaattaaaa attagccagg catggcagca tgcatctgtg gttccagcta ct #tgggactc  14760 tgaggaggga ggattgcttg agcccaggag gttgaggctg cagtgagcca tg #attgtgcc  14820 actgcattcc agcctgggtg acagagcaag aacttgtctc aaaaaaagaa aa #aaaaaaat  14880 tctagaacct cagaagccta gatccacata aacttagaaa catccaattc aa #gaatttac  14940 tggaacaatc aaattctaga atcttagaag cctagagcta aagaagcata ga #aacatcaa  15000 attctagaat cttgtatgta tagaatccta gaaccttgga atctgcagat tc #tggaggta  15060 gagaagccta gaattgtaga accctagaac tgtcaaattt tagagtttag at #atataaca  15120 ccctaaaatc ttggacatta aagagtctta gaagtgttga ctcatagatg tc #tagagttc  15180 tagaaacttg gacatcaaac tctgaagcct tagaaatacg gaatcaggtc ag #gggcagta  15240 gctcacacct gtaatcccag cactttggga ggcttaggtg ggtggattgc tt #gagcccag  15300 gagttcaaga ccagcttgta caacatggaa agaccccatc tctacaaaaa at #acgaaaaa  15360 ttagccaggc atggtagtgc gtgcctgtag tttcagctac tcaggaggct ga #ggtgggaa  15420 gatcgcttga gcctgggagg cagaggttgc agtgagccga gatggtgcca tt #gcacactc  15480 tagtctgggt gacagccaga ctgtttctta aaaaaaaaaa aaaaaaaaaa aa #accagaat  15540 catagaacct tcataaaata ggtttttagt aaactctaga atcttcgatg ta #tagtgtcc  15600 ctagaaccgt ggaaacactg aactctacag caatggttct cgaccagggg cc #gttttgct  15660 cctaggggat gtttggcaag ggttggagat ggttttgttt ggtacgctgg ga #tagtgcta  15720 ctggcatcca gtaggtagaa gtcagagatg cagctaaaca tcctacaata ca #cagagcaa  15780 gtgccctaaa acaaggaatt atcctgggca ctgtgttagt gtcacgggtt ga #ggaaccca  15840 gccctagggt gttcagagtc tggagtcaca gcacattaga accaataaca ca #cacacaca  15900 cacacacaca caagtcgggc gcggtggctc acgcctgtaa tcccagcact tt #taggaggc  15960 caaggcaggt ggatcatctg aggtcaggag cgcgaaacca gcctgaccaa ca #tggcgaaa  16020 ccccgtctct actaaaaaca caaaaaaatc agctgggcgt ggtagtgggc gc #ctgtagtc  16080 ccacgcccag ctaatttttg tatttttagt agagacgagg ttttaccatg ta #gggcaggc  16140 tggtttcgaa ctcctgacct caaatgatct gctctccccg gcctcccaaa at #accgagat  16200 tacaggcggg agccactgca cccagcagtc gtcgggattt tgagtctagc cc #tcctactt  16260 aatcaagacc cccccgatgg ttgggaaaac tgtggctgaa agtgggaaaa tg #accagggc  16320 agcagcagcc agtgttctta cccagacagc aagagtagac tcttttgagc ct #gaggctta  16380 gggtcaaggt tcaagccttc caggtaacct ctcttcccct tctcacccgt tc #ccttgttc  16440 cctgtcctac cagactgcaa gtttaactgt cacaaacgct gcgccacccg cg #tccctaat  16500 gactgcctgg gggaggccct tatcaatgga ggtgagaggc tggggggatg ct #ggggagaa  16560 aggggaaggg gcaggactgg gtggagaccc ctctgatgcc tccgtcccca ca #gatgtgcc  16620 gatggaggag gccaccgatt tcagcgaggc tgacaagagc gccctcatgg at #gagtcaga  16680 ggactccggt gtcatccctg gctcccactc agagaatgcg ctccacgcca gt #gaggagga  16740 ggaaggcgag ggaggcaagg cccagaggta tacacagaac cctccaagag ac #cctggggg  16800 aagaccctcc tgcacagtga acctcaattt ctttttctct acaatgggct ga #catcacct  16860 catatttata aattttccca gttcctgagg caaacctttt aaagcactac aa #tttttttt  16920 aaataatttt ttgtttgaga cagggtctcg gtctgtcgcc caggctggtg ca #gtggtgca  16980 gtcttgactc actgcagcct cgaccacctg ggctcaagcg atcctgccac ct #tagcctct  17040 cgagtagctg ggaccacagg ctcgtccacc acacccagct aatttttgta tt #tctgtaga  17100 gacagggtct accctatgtt gcccaggctg gtcttgaact cctgactcct ga #gctcaagt  17160 gatccacccg cctcagcctc ccaaagggtc ttgctttgtt gcccactgga gt #gcagtggt  17220 gtgattgtgg ctcactgtaa cctcaaactc ctgggctcag gtgatcctcc tg #cctcagcc  17280 tcccgagtat ctgggactac agggatgcac tgctatccct ggctaatttt ag #acggcgtt  17340 tcgctcttgt tgcccaggct ggagtgcagt gatgcaattt cagttcattg ca #acctctgt  17400 ctcctgggtt caagcgattc tcctgcctca gcctcccaag tagctgggac ta #caggcacc  17460 cgcccaggcc cagctacttt ttttgtattt ttagtagaga cagggttttg cc #atgttggt  17520 caggctggtc ttgaactccc aacctcaggt aatccacctg cctcggcctc cc #aaagtgct  17580 gggattacag gcatgagcca ccgcgcctga cctatattcc tcttcttttt tt #tttttttt  17640 tttttttaag atagggggtc ttgctatgtt gcccagggtg gtcttgaact tc #tgcgctca  17700 agcaatcctc ccacctcagc ctcccaaagt tctgggatta caggtgtgtg cc #actgtgcc  17760 cccagcctac acatttttaa actatacacg gagttcatac ttagtcagct cc #actggaat  17820 gtgagctcag gtgcatgagg gcaaggatat tttctgccct cccaggtgcc ta #ggacagga  17880 ctggctcaga tcaggcactt cctatctggg tgtggcgtga atgtttattg ag #aaagcaca  17940 gttcacacag gcgctggagg gtgacagccc agatcccagc tctaccactt ca #cttgctag  18000 gcgcttccct gtgtgccacg gtttcctcct ggggcgatga ggtacctacc cc #acggggtg  18060 ataaacctgg ggtaggggta agggggcacc ctcacaggtg cactggaaaa ta #tttaatga  18120 gcacctgctg tgttcaagca cacagctatg aacaaaagag gtaaaagtct gc #ccttctgg  18180 agctgactgc ctcagtgggg agacagctaa taaatgcatc catagcatcg gg #tattggta  18240 atggtgataa aaacaagagg agatggagaa tgggggacat gctatcttag gg #tccttcaa  18300 ggagacctcg ctgaggaagt ggcagttgaa gggaggggag ggaaggagcc tt #gtggggct  18360 ctgggggaaa aggcttccag gcagaggcaa cagcgagtgc aaaggccctg gg #gtggaggc  18420 accgtgttcc agggacagca aagagaccca tgtagctgca gcagggaggg cg #aggggaag  18480 agggttggac agaaagggga tgggtaagcc agtcacagtg acgacagagt gt #ttcctgcg  18540 gtgcctccca acccaagcag cctgaagccg caggttccct ttctcccacg tc #tttcctgg  18600 gaatgcctag taacaccgtc atacactgtc aagagttgga ccttgaggga tt #gggggtgg  18660 cgggtgtggg gagaggcagc ccatttcaca gatggggaaa ctgagtctca gg #caaagaga  18720 tgtgatcaag gccacccagg ttctgatcta gcacagggat ccagagattg tt #ggttccag  18780 agttgagcaa gtcacttaat ctctcaaatc tcaaactcct gacctcaagt ga #tcccccca  18840 cttctgcctc ccaaagtgtt gggattacag gcatgagcca ccatgcccag ca #ggccactt  18900 aatctctgta gaccttcctt actgtactaa cagcatctgc acaaatgagg ga #ggtgaggc  18960 ccagagaggt tgaatcactt acccagtgtc acacagctgg ctccacaatt gc #tggactaa  19020 ataccaatta gcacttactg gaggtcctct gtatgccagg cactgtacta ag #ctccgtag  19080 aaaggtttcc attcctcata gcatcccctt tgggtggaca aactgaggca tg #aagaggtt  19140 aggtaatttg ctaggcagcc tgacttcaga aaggcctact acagaagccc tc #tcaagaat  19200 ctccttctgg gccagcgtgg tggctcacac ctgtaagcac tctgggaggc cg #aggcggat  19260 ggatctcgtg aacggattct aagggtggga ctaggggcag gagttaggga ag #gagttgag  19320 gcaaagagtt cgagaccagc ctggccaaca tggtgaaacc tcatcactac ta #aaaataca  19380 aaaattagcc aggggtggtg gcgtgcacct aatggtcacc gtgattgtcc cg #gccactca  19440 ggaggctgag gcacgagaat cgcttgaacc cgggaggcag aggttgcagt ga #gccgagat  19500 cgcaccactg cattccagcc tgggtgacag agcgagcctc ttaaaaacaa ac #aaaaagca  19560 actcccgggt gtgtgttggg gggaaaatgt caaaacaaac caaacaaaca aa #aacagtcc  19620 ccaactccct agtttcccag agatgccccc tgcattccca agcagcatgg tc #actttctg  19680 catgtgactt ctcacccctt cctcttcctt cgcagctccc tggggtacat cc #ccctaatg  19740 agggtggtgc aatcggtgcg acacacgacg cggaaatcca gcaccacgct gc #gggagggt  19800 tgggtggttc attacagcaa caaggacacg ctggtgagtg gccggggcgg gg #ccgggtac  19860 ggcggagcga aggctggaag aggggcggct cagcttgagt aggcggggct ag #gtgggtgg  19920 ggctggagct aggcgcgagc ggggccagta gtgggctggg ccgtgctgga gg #cggggcta  19980 gaattagaag tgtgggctgt aagggtggga ctacgggcag gagttaggga ag #acccgggg  20040 ctcagggcaa ggtcaggggc ggggctagag ttaggggagg agcttggctg ga #ggaagagg  20100 gctaagtggg ggcgagtctg gggttagggc gtgggggctg ggctagggtt aa #ggctaggg  20160 gcggggctgg ggttagggcg tgtggtgggg tggggttacg gcgtggggta gg #tgctagag  20220 ttacggcgtg cacgtggtgc tccaggcacc tggagcccca agcagctcca cg #ggataggg  20280 actgggcagg aaagtctggc ggttcacgtg actcttcaaa catctctgca ga #gaaagcgg  20340 cactattggc gcctggactg caagtgtatc acgctcttcc agaacaacac ga #ccaacaga  20400 tactataagg taagcctccg ggctttcagc tccctcggac ttcccgctgt gc #ccacaaac  20460 tttcccacac ctcctcctac ccccagttac tccagacaga tcctgcaaat ca #caccctct  20520 gcccaccccc agcctccctg cttccagctc atcagcaagt gctgcccatc cg #attctggc  20580 cccaccactt tccagccagg gggactccgg gcaggttccc ttacttctca gt #gcctcacg  20640 cttctcacct gcaaaatgcc tcaaatgcta atactcacct cagggctggt gc #gagaattc  20700 aaagagccaa tccactaaac caattggctt aaggcgtggt atatattaag ct #cccagtaa  20760 ttctaaggct gttctcacta ttcctttatt ttttgttatt tatttatttt tt #gagacaga  20820 gtctcactct gtcgcccagc tggagtgcag tggcgcgatc tcggctcact gc #aacctccg  20880 cttcccgggt tcaagcgatt ctcctgcctc agcctcccac cctaggacta ca #ggtgaatg  20940 ccaccacacc cagctaattt ttgtattttt agtagagacg gggtttcacc at #gttggaca  21000 ggatggtctt gatctcttga cctcatgatc tgcccccctc ggcctcccaa ag #tgctggga  21060 ttacaggcat gagccaccgc acccggcctc actatttctt tataattaat gt #attgcatt  21120 gtgtgcgtat tcgtcaccac ctcccatgcc cacactgtgt cccagccact gt #cttccacc  21180 tggatggttt cagccttctc cttgcagggt ccttgcttct gacctcacaa cc #tctgtcat  21240 ttcccccaca gccaggggga gtcttcatta aaaccgtcaa accccccagt gg #ctcccatt  21300 gtcttagaag taataaaacc tggtactcca gctgttacct gccctggaag cg #tcttcctt  21360 gaactttcca tggctggttc cttatcatct tcccattttg ctcagaccac ac #catctaaa  21420 atgctgtcct tggccaggcg tggtggctca cgcctgtaat cccagcgctt tc #agaggccg  21480 aggtgggcgg atcacttgag atcatgagtt cgaaaccagc ctggccaata tg #gtgaaacc  21540 ttgtctgtac taaaaataca aaaattagct gggcatggtg gcgggtgcct at #aaccccag  21600 ctacttggga ggctgaggca ggagaattgc ttgaacctgg gaggtggagg tt #gcagtgag  21660 ctgagatcgc gtcactgcac tcctgcctgg gcaacagagc aagactccat ct #caaaaaaa  21720 taaaataaaa taaaatataa tgctgtcctc accatgcccc cccgacgtgt cc #atgtcatc  21780 acctggtttt atgggctgcc taagtcattc attctttcct ctctcctacc tc #cctccttc  21840 ctcttttgac acgtttccca ccccatagtc cctgtgcctt ctgtcccgcc tg #ggtcccct  21900 cagcctcctt cctggttctc tgtctccatc tcattctatt ccatctgccc tc #cgcacaca  21960 agcggatgat gctcaaaagc cttcagtggc ttcctagggc ccttggacaa ag #cccaggct  22020 cttccttgtg gcccgcaaag ccctgtgtgg cctcatttcc tccatttatt at #caaacgtt  22080 tatttttgag acggagtctc gctctgtcac ccaggctgga gtgcagtggc gc #gatcttgg  22140 ctcactgcaa cctccgcctc cggggttcaa gtgattcttc tgcctcagcc tc #ccaagtag  22200 ctaggattat aggtgtgcca ccacgcctgg ctaatttttg tatttttagt ag #agatgggc  22260 tttcaccatg ttggtcaggc gggtctcgaa ctcctgactt tgtgatccgc ct #gccttggc  22320 ctcccaaagt gttgggatta caggcatgag ccaccatgcc cagcccattt at #ttattttg  22380 agacaggctc ttgccctgtc tcccaggtgc agtggcatga tcatggctca ct #gtaacctc  22440 tgcctccctg gctcaaatga ttctcccacc tccacagtag ctgggattac ag #gtgcgcac  22500 caccacacct ggctagtttt tttatttttt gtagagatgg gggtctcatt gt #gttgctct  22560 ggctggtctc aaactcctgg gctccagcga tctgcctgcc ttggcctccc aa #agtgctgg  22620 gattacaggc ttgtggcacc atgcctaatt tttaaatttt ttgtagagct gg #ggtctcac  22680 tgtgttgccc aggctggtct tgaactcctg ggccatctgc ccacctcggc ct #cccaaagt  22740 gctgggagta caggcacgag ccaccacatc cggccatcaa aatgtttatc aa #gcttttac  22800 tatgtccagg caccgcccca tgtgatgggg atacagcttg gcttttgagc at #agcctttc  22860 cttagggcct ttgcacatgc tgttccccta ctcccttgcc aactggctgc tt #cttacctt  22920 tctggtctct gcttcaatat cacttctgcc agtaattagt attattatta tt #atttttga  22980 gacggaatct cactctgtcg cccaggctgg agtgcagtgg tgcgatcttg gc #tcattaca  23040 accaccgcct cccaggtgca agcgattttc ctgcctcagc ctcccgatta gc #tgggatta  23100 caggcgcaca ccaccacgcc tggctaattt ttgtattttc agtagagacg gg #attttgcc  23160 atgttggcca ggctggtctc gaactcctga cctcaagtga gctgcccacc tc #ggccttcc  23220 aaagtgttgg gattacaggc atgagccacc gcacctggcc tctgccagta at #tataaaag  23280 aacagtgaga acaggcttag aattactggg aacttgtctg accactgtgc aa #accaggcc  23340 catccctatc aacatggatc ccgtgtatcc ttctgggtaa gcactagaat tc #caaggtct  23400 gcctggcatc ctcacctgtg ctggttccac gtcctgcagg aaattccgct gt #cagaaatc  23460 ctcacggtgg agtccgccca gaacttcagc cttgtgccgc cgggcaccaa cc #cacactgc  23520 tttgagatcg tcactgccaa tgccacctac ttcgtgggcg agatgcctgg cg #ggactccg  23580 ggtgggccaa gtgggcaggg ggctgaggcc gcccggggct gggagacagc ca #tccgccag  23640 gccctgatgc ccgtcatcct tcaggacgca cccagcgccc caggccacgc gc #cccacagt  23700 aagtcctccc acctcgggtc cttgagagaa tagatctaga tgggtggggc ac #ggttctgg  23760 ggaatggaag ggccaaagag gaaagtgggc aatggtgggg ttgagaacgc ag #cttctgga  23820 ctcagcaggc ctgggttcaa actctgttaa tcactcctgt taatcccagc gc #tttgggaa  23880 gccaaggagg gaggatcact tgaggccagg agttcaagac cagcctgggc aa #cataatga  23940 gattccatct ctacaaaaaa taaaaacaat tagccaggtg tggtggtgca ca #cctgtagt  24000 tccaggtact tggaaggctg aggcaggaga attgcttgag cctgggagta gt #gagtcatg  24060 attgcatcac tgcactccag tctgggtgac agagcaagac tctgtctcca aa #acagaaaa  24120 aacaacaaca acaaaaatcc acaacaaatc tctgttaagc tcctggcctg at #atgtggcc  24180 ctgggcatat cacttcccct ccatgagcct tgtcccaggt gctgataagt cc #tcatgcac  24240 ttactgagtg cctcctctgt gcgggacagt gctggggacc cagtggtggc ca #ggacagcc  24300 caagacctgc cctcatgggg ctcagagtcc agtagggcag aatacccatc tt #cagagagt  24360 gacagtccag ggtgggcagg gttgggacaa ggaagctagg gagctggagg ag #cccagagg  24420 ggtacctgac ccaatctggg tatatagggg ggcttcctgg aggaggtgac at #ctgaactg  24480 agatctggag gccgaggcag ggtgagatgt gggaaagaaa atgggaggtc at #tttaggca  24540 gaggcaaaaa atgttgagag agtaccaggt tcccaccctc tggagcttat aa #tccagtgt  24600 gggtgacaga cattgatcat taacccatac aagcaacgag tgtgatgcag ag #catttgcg  24660 agagtaatcc aacttggtcc taggagtgac atttgagctt acacttgagg at #gaggagga  24720 tttagctaag tctaggatga aggaaagagt attcctggca ggggaaacag ca #tatgcaga  24780 gaccagaagg cagaagagag tttgctgtat ttgaggccga gcaaggaggc ca #gtgtgtca  24840 ggaatagcat gttgggggta gaagtcagag gtagatgagg gtctaggcca tg #gcttttag  24900 gccatttaag gggctcaggc ttcttcctga gggcactggg gagccatggc ag #agttgtga  24960 gcagaggagg gacagggtca gtcttgtgcc tcagtaagat ccctctggtt tc #tctgtggg  25020 aggtgagtag gaaggggcag gattggggca aggagaccag ggaaggggct gt #ggggtgag  25080 gacccagagt tggggggcga gcaggggcct agactggtgg aagagagaga ca #ttcaaatg  25140 gcagaaggat cggactttag aaatgtctgg ctctggttgg gtttgtaggg gg #aaaagttc  25200 aagggaagat gcaggagtca gtctgggctt tccctccaag actcagtttc ct #tctctgta  25260 caatggggtc agtctgcctc ccctggtgct gagatcctgg ggtaaaatgc tc #agcaaaat  25320 catctgtaac atcactcctt tagccactca gcacatctca tttactcctc ct #ggtggctc  25380 tatgagggag gtccttttat tattcccatt ttctagatga ggaaactgag gt #tcgtagtg  25440 gacaagtcac cagcctgaag ttgcacattg tatcgaacat tggattcaaa tc #tgggtggc  25500 ctgactccca agtctgcttt tgcaggtatg ggtggagata atcctgagcc tg #gagtcccc  25560 tcacctctgt ctctcccctc tccctaggac aagcttctct gagcatctct gt #gtccaaca  25620 gtcagatcca agagaatgtg gtgagacttc ctgcccccac ctgatgccct cc #cctcccac  25680 aaaccctcct cagctctctc gtctccttga ctcccccttc cccatttcca tt #tgcacccc  25740 tgacctgccc tgtcttcacc ctgtaggaca ttgccactgt ctaccagatc tt #ccctgacg  25800 aagtgctggg ctcagggcag tttggagtgg tctatggagg tgaggacact tc #agagctaa  25860 cccagaggga gccccgggct gggggaagct gctgtggctc cagccctttc tt #tctggctc  25920 caacccttcc tttctgattg gtcacatgct cacctcccat gttgattggc tt #agctagat  25980 cctgggtgga ctgattgcag gttctccttt tctcattggg aaaaaccaat gg #acattcct  26040 cctgttatta ataggaaggg taaattcggc actctgattg gtcacagagg ta #gattttga  26100 ttggataggg aaggtagatt ctgcactctg attgaccaca gagctagaac ct #agattctg  26160 attggataga gtagattctg cattcatatt ggccacagaa ctagttccta ga #ttctgatt  26220 ggaaaagagg gtagattctg cactctggcc acagagctag atcctagatt ct #gattgaat  26280 aggagggtag attctgcatt ctgattggcc acaggtctag atcctagatt ct #gattggat  26340 tggagggtag attctgcatt ctgattggcc acaggctaaa tcctagattc tg #attgtatg  26400 gggcgggtgg taaattttac actttgattt gccacagagc tagatcctag ag #ttcaatag  26460 gacagggagg gtaacttcta cactctaaac tctaagactc agtttccttc tc #tgtataat  26520 agggtcagtc tgcctcccct ggtgctggtg tctctcccct gtccccagga ct #cttatggg  26580 tcacacaaaa ctagatgcta gattccgact ggttataaat ccagtttccc at #gttataca  26640 ttcccttctt cggagctttt tgtttgtttt ttgctttcct tctttctgcc tt #tactccca  26700 aggtgcacct caggtggcct tttcacgtat ctcctggggc cttccaactc tg #cccaactc  26760 tggctgtctc catggtgggg ggcagaggtt ggcagaggtg gagatactcc tg #ccaggact  26820 gggtggtctt gctctctcat cccccatctc ttctactccc tgtgcaggaa aa #caccggaa  26880 gacaggccgg gacgtggcag ttaaggtcat tgacaaactg cgcttcccta cc #aagcagga  26940 gagccagctc cggaatgaag tggccattct gcaggtaacc accaggccgc ct #tccctttc  27000 tgcttcttcc tttcatgggc cagctgaccc agtgtagggg tggtcaggga ag #gcttcctg  27060 ggggagggca tgtgcatgtt gagactgaag gggagaaggt gttcttagca ga #gggaccag  27120 cctgtacaaa gacctggtga gagggagcat gaggttttct agaaaggagg ta #ctgggaga  27180 tgaggccagg gaggagggcg gagccagacc ctttggactt tctcctgagg gt #actggaga  27240 gccacagaag gcttttgagc aagggagggg caggatcagg tgtgtacgtt ag #gaaaatcc  27300 cgcaggctgc catctggagg gtgggtggaa agggaagtga ttgtagccag ga #ggctgagt  27360 ggggatctgg gtgggagaga ggggttaggc caggatagga ctggagaatg tg #agaggggg  27420 tatggattta aaagatacag atgtgcagag ctctccccat ttctccaagc tc #cccctcct  27480 ccctcctgca accctgggcc tccaccagaa tttcaggatg taaagatcct tc #tgggccgg  27540 gcatggtggc tcacgcctgt aatcccagca ctttgggagg ctgaggtggg ag #gatcactt  27600 gaggccagaa gtttgagacc agcctggcca acatggcgaa accccatctc ta #tatttaaa  27660 tagaaagaaa aaaaagatcc ttctgggcac ctggcaggtg gggtggaggt gg #gcctgttc  27720 tgtcttggcc tgtgggaagc ccccttccct ctccaagtgc caatacccca gg #gacatcct  27780 tctccttgtt tgtcatcctc ctgctcctat acctgacccg ttggggtctg ag #tttgtggg  27840 ttacctgggc cctgaccccg ctccccaccc tgcagagcct gcggcatccc gg #gatcgtga  27900 acctggagtg catgttcgag acgcctgaga aagtgtttgt ggtgatggag aa #gctgcatg  27960 gggacatgtt ggagatgatc ctgtccagtg agaagggccg gctgcctgag cg #cctcacca  28020 agttcctcat cacccaggtg cgtctgccct gcccgctgcc acccgcccct cc #ccatcagg  28080 tgtcagcttg gagaggccct gtatgcctag ggggtcaagc agacacttgg gg #gagtcaca  28140 atagcagata acagaaacca tcatcaggct gggcgcagtg gctcacaccc gt #aatcccag  28200 cactttggga ggcccacgag gtcaggagat cgaaaccatc ctggctaaca tg #gtgaaacc  28260 ctgtctctac tagaaataca aaaaattagc cgggcatggt ggcaggcgcc tg #tagtccca  28320 gctactcggg aggctgaggc aggagaatgg tgtgaacctg ggagatggag ct #tgcagtga  28380 gccgagatcg cgccactgca ctccagcccg ggcgacagag caagactcca tc #tcaagaaa  28440 aaaaaaaaaa aaaaaaagga accataatcg tacagaagta ataataacca ta #atagaaaa  28500 aataagccgg gcatggtagc acgtgtctgt ggtctcagct actcaggagg ct #gaggcagg  28560 aggatcactt gatcccagga gttctgtgct gatcaggtgt cctcattaag tt #tggcatcc  28620 atgtggtgac ctcccaggag tgggggacca ccaggttgca aagcagccca gg #ttggaaat  28680 ggagcaggtc aaagctctct tactgatcag tagtgggatc acatctgtga ag #aggcattg  28740 cactccagcc tgggcaacat agcgagaccc cgcctctaaa aagaaagaaa ga #aaaaagaa  28800 aaataatagt gacaataaca attaaaaata aagagtatgc caggcgcggt gg #ctcacgcc  28860 tgtaatccca acactttggg aggccaaggc gggtggatca cctgaggtca gg #agtttgag  28920 accagcctgg ccaacatggt gaaaccctgt ctctactaaa aatacaaaaa tt #agctgagc  28980 atggtggcag gcacctgtaa tcatagctac ttgggaggct gaggcaggag aa #tcccttga  29040 gcccaggagg cagaggttac agtgagctga gatcgtgcca ttgtactcca gc #ctggggga  29100 caagagtgaa acttcgtctc aaaaaaaaaa aaaataataa taataataat aa #agagtaat  29160 cataataata gaaaaaaata gactagcggt aatgatagct atttttatta ta #aaaaataa  29220 atgatcagtc aggctccctg gacctgactt gactcatcta gaaaaaaggg ga #gtcaggca  29280 tggtggggta cacctgtaat cccagctact caggaagcta aggccagagg at #tgcttaag  29340 cccaggagtt tgagccagcc tgggcaacat agcaagagcc catctcaaaa ac #aggctggc  29400 tcatgcccgt aatcccagcg ctttgggagg ccaaggcaag aggatcgctt ga #agccagga  29460 gttggagacc agcctaggcg acatagtgag atcccacctc tacaaaaagt aa #aaaaaaaa  29520 atagaaaacc tagctggatg tggtgcctgg tagcacatgt ctgtagtcct ag #ctgcttgg  29580 gaggaaggga gtggagaggc tctcttgaac ctaggtggtt gaggctgcag tg #agctatga  29640 ccgtgccact gcactccagc ctgggtgaca gagcgagacc gtgtctcaaa ac #caaacaat  29700 agaaaaaacg ggcaagcagc cctttttctc tcattcattc attcagttgg tc #aacaaaca  29760 ctccctagtc cctgctctgt gcttggtccc ttgctggtca gtgttgagga ca #cagggatg  29820 accaatacag ccccattctt agacagtgat agctcaggtg agcagggcta gg #acaaggga  29880 ggctgataat ggtgatgata aataatgtgg tcactaacat ttattgagca ct #tactatgt  29940 gccaagcact cttcaaactc atttaatctt catagtaacc tgtgcagtag gt #gctattat  30000 tatcaatccc cttttatggt tgaagaaact gagggtcaga gacatcaaat at #cttgtcca  30060 gggtcacata gctggtggga tttgaaccta ggatctttgc ttttaactag tg #atgtcaaa  30120 ctcatttgtg ttacattcaa acagattttc cttgtgtgcc tgtgtgcctg tg #ctttttgt  30180 ttgttttttt gagacagggt ctcgctctgt cacccgagct ggagtgcagt gg #tacaatca  30240 tggctcactg cagccttgac ctcccgggtt caagcaattc tcctgcctca gc #ctcctgag  30300 tagctgagac aacaggcatc agccatcaca cccagctaat ttttataaag ac #atttttat  30360 aaagacttgc tatgttgccc aggctggtct tcaactcctg ggctcaagtg at #cctcctga  30420 ctcggcctca gcctcgcaaa gttctgggat tacaggtgtg agccactgtg cc #cggcctct  30480 gttctgcgtt tctttttttt tggtggaggt gcacattaga ttcttatcac tt #atattgtt  30540 caatggtttt atcccagtgt ttgcctcttt attttatatt tagtttttat tt #accatagg  30600 gttttattta ttttattttt tatttttttt tgagacggag tcttgctcta tt #gcccaggc  30660 tggagtgcag tggcaccatc tcggctcact gcaagctccg cctcccaggt tc #acaccatt  30720 ctcctacctc agcctcccaa gtagctggga ctacaggtgc ccaccaccac gc #ccggctaa  30780 ttttttgtat tttcagtaga gacagggtct cactgtgtta accaggatgg tc #tcgatctc  30840 ctgacctcgt gatccacccg cctcggcctc ccaaagtgct gggattacag gt #gtgagcca  30900 ccgcgcctgg cctattttat tttttttttt gagacagggt ctcattttgt ca #cccaggct  30960 ggagtgcagt ggtgtaatca tagttcactg cagcctcaaa ctcctaggct ga #agcaattc  31020 tcctatctca gcctcctgag ttaactggaa ccacaggcat gagccaccac gt #ccagctaa  31080 tttttttttt tttttttttt aatgtttttg tagagacaag gtctcgccat gt #tgcccagg  31140 ctggtcttga actcctgggc tcgagcgatc ctcccatctc agtctcctga gt #tagctgga  31200 accacaggca tgagccatta cacctggcta attttttttt atgtttttgt ag #agacaggg  31260 tcttgccatg ttgggtctcg aactcctggg cttaagtggt cctcttgctg ca #gcctccca  31320 aagttctggg ttacaggcat gagccactgc gtccagccgg ccatagagtg ga #acttttac  31380 gatgttaaat atccccttgt gtggtttctg tgtttcacat ccttcctaga aa #ggcttcct  31440 tctggtgggt gccttgcctt cttctgagac atctctgtgg gtctcagagc ca #tcgttgct  31500 gtgttccctt taccctggcc cagcaccctt atcctctcag gcagtgtgcc tg #tgtttgtc  31560 aggctggctt atggggtggg gacagaaacc cactgatgca ccctcatcca ga #ctttatta  31620 tttatgtatt tttgagacag agtctcgctt tgttgcccag gctggagcgc ag #tgacacga  31680 tctcggctca ctgcaccctc tgccccctgg gttcaggtga ttctcctacc tc #agcctccc  31740 gagtagctgg gattataggt gtgtgccacc atgcctggct aatttttgta at #tttagtag  31800 agatggggtt tcatcatgtt gcccaggcca gtctcaaact cctgacctca ag #tcatctgc  31860 ctgcctcagc ctcctgaagt gctgggatta caggcatgag ccatcgtgcc cg #gccacatc  31920 cagacttcag gtgtggaaag gaatcatggt tctcacaggt ggctgctttc ag #cagctgag  31980 ggggtttctc tttctggcct tcatctcttc ctctcttttt gcctgctcgc tc #ttctttct  32040 ctctctctct ctctctgcag atttctgctt tctgggctct tgcctgcccc ac #acctaagc  32100 cctgtgctaa gccctttacc tcctgagctt atgtaggcct caccaccatc ct #aggaggta  32160 ggtattgtta taaaccccat tttatagatg aggaaactga ggctcaggga gt #tagcagtc  32220 tccctcgagg tcacagccaa gtagctttcc agccaagatt tgagtctgga tc #tatctagc  32280 ttccaacctg ccctctttct tttctttttt tttttttttt tttgagacga ag #tctcactc  32340 tgtcacccag gctggagtgc aatagtacag tctcagctca ctgcaacctc tg #cctcccag  32400 gttcaaacaa ttgtcccacc tcagcctcct gagtagctgg gactacaggt gc #gtcccagt  32460 acaccgggct aatttttgta tttttagtag agacggggtt tcactatgtt gg #ccaggcta  32520 gtcttgaact tctgacctcg tgatccaccc gcctcagcct cccaaaatgc tg #ggattaca  32580 ggcgtgagcc accatatccg gccaatgttt tttttttttg gagatggagt ct #cgctctgt  32640 tgcccaggct ggagtgcagt ggcgctatct cagctcactg caacctctgc ct #cccaggtt  32700 caaatgattc tcctgcctca gcctcctgag tagctgggaa cacaggcaca cg #ccaccatt  32760 cctggctgat ttttgtattt ttagtagaga tggggtttca ccatgtcgat ca #ggctggtc  32820 ttgaactttt gatctcgtga tctgcccgcc tcagcctccc aaagtgctgg gg #attacagg  32880 cgtaagccac cgtgcccggc ctaacctgcc ctctttgttc acatgaactg gg #agaaaatc  32940 aactgacaaa atctggaaat gggcggggcg aggtggctca cgcctgtcat cc #tagaactt  33000 tgggaggcca aggcagatgg atcacctgag gtcaggagtt ttgagaccag cc #tggccaac  33060 atggtgaaat cccatcttta ctaataatac aaaaattagc caggtgtggt gg #cattcacc  33120 tgtaatccca gctactgggg aggctgaggc acaagaattg cttgaacctg gg #aggtggaa  33180 tttgtggtga gtcgaggtca tgccgttgca ctccagcgtg ggcaacagag tg #agactcca  33240 tctcaaaaaa acaatctgga gatgacatat acaacacatg catctttcca gc #ttggtctc  33300 ccagtctgta gaatgaggag gttggtcagg catggtgggt cgtgcctatt at #ctcaaggt  33360 ttgggtagct gaggtgggaa gatcatttga ggccaggagt tttagaccag cc #tgggcaac  33420 atagcgagat gccatctcta caaaaagatt tttttaaaaa agaaaacaat ca #gaataaac  33480 acaagtattt aaactctgag acagatacac aagtatttaa actccgagac ag #ataataat  33540 tgcagttgta caacactcta tgcttctggt gtacttggca ttttgagtta ca #gagaatca  33600 agaaatatga ttctcacaga tgaatggtta caaatggtaa tttttttttt aa #tcagctca  33660 ccttatcata ggaacagata cagcaggaga agctttattt aagagacaca aa #caaatata  33720 tttaccaaca agccatcaca aaaataataa ctaataacaa caacagtaac ag #ctaacata  33780 cagtggttag ctatcctaag cgttttacat gcatctttag atatgcttta aa #ccttatag  33840 caacctgtaa ggttggtact cttttttttt ctgagaggca tctcactctg tc #gcccaggc  33900 tggaagtgca atggcgcgat gtcgactcac tgcaacctcc acctctccag tt #caagcgat  33960 tttcctgcct cagcctcccg agtagctggg actacaggcg cccaccacca cg #cctaattt  34020 ttgtattttt aatagaggca gggttttgct atgttggcca ggatggtgtc ta #actcctga  34080 cctcaggtga tccacctgcc tcagccttcc aaagtgctga gattacaggc at #gagtcacc  34140 atgcccagcc aaagtttttt gtaaggatga aaaatatttt ttttaaaaat ga #aatcaggc  34200 tgggcacagt ggctcacgcc tataatccca gcactttggg aggccaaggt tg #gtggatca  34260 cgaggtcagg agttcaagac cagcctgacc aacatgatga aaccccgtct ct #actaaaaa  34320 tacaaaaatt agccgggcat ggtggtgtgt gcctgtaatc ccagctgctc ag #gaggctga  34380 ggcaggagaa tcaggaggcc ttctcaaaaa aaaaaaaaaa aaggaatcaa ag #cccgacat  34440 ggtggtggtg gcacatgcct gtagtcctag ctatttggga gactgaggct gg #aggatcac  34500 ttaaccccag gagtttgagg ctgtagaatg atactgcact tcagcctggg tg #acagaggg  34560 agactccatc tcttcaaaaa aaaaatgggt gaggtggggg tggctcacgc ct #gttatcca  34620 agcactttgg gaggctgagg tgggtggatc acttgagtgc aggagtttga ga #ccagcctg  34680 ggcaacatgg tgagacactg tctctacaaa tacaaaaatt agtcaggtgt ga #tggtgtgt  34740 gcctataatc ccagttacta gggaggttga ggtgggagga tggatttagc ct #gggaggtc  34800 gaggtgcagt gagctgtgat cccgcctctg tgctctggcc tgagtgacag ag #caagactc  34860 tgtctcaaaa aaaaaaaaaa aaaaaataga atcacatagt tggatcttgg aa #atgcctgc  34920 tctgtgagta gcattcagga gtttaccaca tgctagaaga tcttgggatc tt #acagcccc  34980 actcatctag cccagacttt ctagtttaca tttaactctt atctctcaga tg #taaatggt  35040 tctatgattc tgagattctt tggtgctcca gtgcctcctg tttccctggc tg #gggtgtct  35100 gcaggggtgt gtaggaaggc atggatgggg ccaggcgcag tggctcactc ac #gcctgtaa  35160 tcccagcatt ttgggaggcc aaggtgggtg gatcacttga gtccaggagt tt #gagaccag  35220 cctggtcaac atggtgaaac cctgtctcta ctaaaaataa aagaaaaaat ta #tcagagca  35280 agtctgggcc cggtggctca cgcctgtaat cccagcactt tgggaggccg ag #gtggggga  35340 atcacgaggt caggagtttg agaccagcct ggccaacatg gtgaaacccc at #ctctacta  35400 aaaatagaaa aaattagctg ggcatagtgg ccagcgcctg taatcccagc ta #ctcgggag  35460 gctgaggcag gagactcact tgagccctgg aggtagaggt tgcagtgagc cg #agatcgtg  35520 ccactgcact ccagcccagg cgacagagtg agactccgcc tcaaaaagaa aa #aaaaaaat  35580 tagctgggca tggtggtgca cgcctgtagt cccagctact tgggaggctg ag #gcaggaga  35640 atcacttgaa cccaggaggt aggggttgca gtgagctgag atcatgccac tg #cacttcca  35700 gcctgggcta cagagcgaga ctctgtctca aaaaaaaaaa aaaaaaagta tg #gatgggtt  35760 tggagggctg gctgctgagg ttgggatttg gctgagtacc tatctacctt tc #cttactgg  35820 gcccatctgc tcccctcaga tcctggtggc tttgagacac cttcacttca ag #aacattgt  35880 ccactgtgac ttgaaaccag aaaacgtgtt gctggcatca gcagacccat tt #cctcaggt  35940 cagttatgtc ccctcctgat ttggggaaat ccaggcaaca ctgatggccg gg #gtgggggt  36000 ggggaagggg attatactaa tcaagatgtg ggggcgaggc acagtggctc tt #gcctgtaa  36060 tcagcatttt gagaggctga ggcaggagga tcatttgagc ccaagagttt ga #gaccagcc  36120 tgggcaacat agcgagacct catctataca aaaaatgaaa aaaaaaatag cc #gggaatgg  36180 tggcgtgcgc ctatagtcct agctgcttag gaggctgaga tgggaggatt gc #ttgagccc  36240 aggagttggt ggctgcagtg agctatgatt gtgccactgc actccagcct ga #ataacaga  36300 gtgagagctg tctcttaaaa aaaaaaaaaa aagactgggt gcggtggctc ac #gcctgtaa  36360 tcccagcact ttgggaggcc gaggcgggca gttcacgagg tcaggagatc ga #gaccatcc  36420 tggctaacac ggtgaaaccc cttctctact aaaaatacaa aaaaaaatta gc #ggggcgtg  36480 gtggtgtgtg cctgtagtcc cagctacttg ggaggctgag ttaggagaat gg #catgaacc  36540 cgggaggcgg agcttgcagt tagccgagat cacgccactg cactccagcc tg #ggtgacag  36600 agcgagagag cgagactctg tctcaaaaaa aaaaaaaaaa atatatatat at #atatatat  36660 atagtttatc ccaacatata gcactttatt caacatgtag tcaacataaa aa #ttattaag  36720 gccaggggag gtggctcatg cctataatcc ccgcactttg ggaggccaag at #gggaagac  36780 ggcttgagac caggagttca agtctgaagt gagctatgat tgtgccactg ca #ctccagct  36840 ggggtgacag agcaagaccc tgtctcttaa aaaagaaaca aaactcaatg aa #acattctg  36900 cttgtttttc atactatgtc ttcaaaatct ggtgtgtata acagttgggg aa #atagattg  36960 acatgcccaa gttgttccaa acatatttaa aagttttctg gttgggcgca gc #ggctcatg  37020 cctataatcc cagcactttg ggaggctgag gcgggcagat cacttgaggt ct #ggagttgg  37080 ataccagtct ggctaacatg gcgaaacccc gtctctacta aaaatacaaa aa #ttagctgg  37140 gcatggtggc gggaacctgt aatcccaggt tctcaggagg ctgaagcagg ag #aattgctt  37200 gaacccagga gggtggaggt tgcggtgagc cgagatcaca ccactgcact cc #agcctgga  37260 cgacagacca agactcgtct caaaaaaata ataataaaat aaaaatttta aa #aaagatcc  37320 ataggaaagt atagatcttg gaaaagagaa agagctataa gatctgtaga aa #gggcagag  37380 tacctcagga aagggtggct gtcacattga gattcaggtc aggggttgag gc #gtggctgg  37440 tttcaaaggt gacagaggct tcaggcttca aggatttggg gctctatcct gc #aagcaaca  37500 gtgagccaag gaagggtttt gaacagggaa aggacagtac atgaacagag ct #gggaacca  37560 aggctgagag gtaggcagca gagcaagacc ttgaacccag gtcttgctgg ct #ccaaagcc  37620 tgtccatgac cttagactgc agccattaac aatgagggta tggggccagg tg #tggtgtct  37680 catgcctgta atcccagcac tttgggaggc tgaggcagga ggaacacctg ag #gtcaggag  37740 tttgggacca gcctggctga tgtggtgaaa tgtcgtctct actaaaaata ca #aaaattag  37800 ccaggcatgg tggcgggtcc ctgtgatccc agctattcgg gaggctgagg ca #ggagaatt  37860 gcttgaaccc gggaggcaga ggttgcagtg agccaagatc acgctactgc ac #tccagcct  37920 gggcgacaga gcgagactcc gtctcaaaaa aaataaaaca atgaaggaaa gg #taggcata  37980 caccatactg tctgccagct accgcagtca gcacccactc ctacctaatc cc #caggaaag  38040 cctgagagga ggctgctatc aacaaccccc caatacagat gacaaaatca ag #gcctggag  38100 aaattaggtc cttgacctga gatcatcgag ggtcattctg tgctagacac tg #ctcctaac  38160 acgttgcata catttctctt tcagtctaaa caagcaccct ttaaggtagg ga #ctgttaag  38220 atctccatta tgtttcatgt tttttttgtt tgttttttga gacggagtct cg #ctgtgtca  38280 cccaggctgg aatgcagtgg tgcgatctcg gctcactgca acctctgcct cc #caggttca  38340 ggcgattctc ctgcctcagc ctcctgtagt agctgggacc gcaggcgtgt gc #taattttt  38400 gtatttttag tagagatggg gtttcatcgt gttggccagg ctggtctcga ac #tcctgacc  38460 tcaaatgatc catcttcctt ggcctcccaa agtgctgaga ttgcaggcat ga #gccaccac  38520 gccccaatca tgtatatttt gaggctatta aaaaaaatct gcattattca aa #agaggaaa  38580 cagcgaccca ttggaggtgg cagaggtata gcagcagcta gcatttattg tg #caccaact  38640 gaatgccaaa tattgtcctg tgggctttgg atggtttaat tcactaacca tc #atggcagt  38700 cctctgagat aggtgctctt ctgctcttct tcctatagat ggggaaactg ag #gcacagag  38760 gggggaagtc acctgcccag ggttgctcag ctagtgagcc aaggagcctg ga #ttcaaacc  38820 agcatccagc tttctctgga ataccatgga gggtggtgtg gtggggatgc tg #gggtgggt  38880 gcggctccat cacctggtgg agcctccatc ccttgccctc tgcaggtgaa gc #tgtgtgac  38940 tttggctttg ctcgcatcat cggcgagaag tcgttccgcc gctcagtggt gg #gcacgccg  39000 gcctacctgg cacccgaggt gctgctcaac cagggctaca accgctcgct gg #acatgtgg  39060 tcagtgggcg tgatcatgta cgtcagcctc agcggcacct tccctttcaa cg #aggatgag  39120 gacatcaatg accagatcca gaacgccgcc ttcatgtacc cggccagccc ct #ggagccac  39180 atctcagctg gaggtgcctg gggcccgcct accccatggg cgggtgggtt gt #ggggtggg  39240 gctggagaag tgggcggagc catgagaggg gggtggaccc ggaaacagcc tg #gcaccttg  39300 ggggtggagc ccagtgctgg ggcgggccta ctggagggat gtggctacag ga #ggagccgt  39360 cctgtaaaag atgggctggg actcaggcct agactaggtt acttgggctg ga #aaccaagt  39420 gccccagaag cgctgaggac acttggaacc ttaggggggc tgagtgagac tt #ggcttgtc  39480 tagggtggga ccaggaaagg gactggactt gagggtacca aagggctgcg gt #gaccagga  39540 gaaggggctg agcctcccaa ggcattggct gggacctgga gcctttgggt tt #acgacccc  39600 aaaagggtca gccttgcaaa aaggaggcac cggtgggtag ggttgagaaa ca #agggcatg  39660 gctactttgc tgtgtactgg ggccgtgact tgggtgaaga tgggcctgaa gc #ctggggtc  39720 ggttcagtga ccaagggagc cagtctaggg acgtggccgt ggagggtttc cg #aagaggtc  39780 caggaacagg gctgaccctg agtcctggaa gctgggagtg gatgggagtg gg #gaggagaa  39840 gggagccagg actgaggcag acattgcact ctgcattctg gggctttggt gt #tgtggctg  39900 ggcctgatga agtggcaccg ggcctggtga cttgaaccta cttgggaatg gg #tctgtaac  39960 tttccctgct tggaaaagtt aagtcctaag gcctggagct ttgaggctgg gt #gtgggatg  40020 gcatgtttag agggccagag gcagggctaa gatactgggg tgtgtcagaa gc #caggagaa  40080 caagggacct gtgttggagc cagggagctc aggaagacag atggagtatg gg #aagggggg  40140 ggatcattca ttcatttatt tataaccatt tattcaacaa gtacattcat gt #atttgtaa  40200 ccattgattc aacatgttga gtgcccacga tgtgccaggc attgactgtt cc #agctctgg  40260 gaatactgtg atgacttgga cagaaggggt caggtgcagg gtagctcatt ga #gtggtccg  40320 cgaagggtgg aaaggggaag ggtcctctct ggagggtgcg gcttcatgga gc #aggtggag  40380 cagggtgaca cggaggttgc tcggtgcagg acaagacaag gtcttggtgg tg #gtctaaga  40440 gcatgggccc taagcagtga gaatgtggat tgacttgagt cctggagtaa ta #ttgggggt  40500 gctcaacact ggcttttttt tttttttttg aggtggggtc tcgctctttc ac #ccacgctg  40560 gagtgcagtg gcgtgatctc ggctcactgc aacctccacc tcttgggttc aa #gggattct  40620 cctgcctcag cctcccgagt aactgggatt acaggcacac agcaccatgc ct #ggctcatg  40680 ttttatattt ttagtagaga cagggtttcg ccatgttagc caggctggtc tt #gaactcct  40740 gacctcaagt tatttgcccg cttcagcctc ccaaagtgct gggattgcag gc #ataagcca  40800 tcacaccccg ccagcattgt cttttgagac ccactcagaa gtccctcagt aa #aagtgcat  40860 cgagtgtgca caagtgaatt taagtgtggt tgcacctgtg tgaggatcac ag #aatcctgt  40920 gggtgttgac gggagcaggg tgcctgtgtg caccaggcct ctcctcggat gg #gttcatac  40980 agtgaagcct tgtccttcat ggcttcccat caaggagaga gcctcggatg ag #tgctggct  41040 tgtcttgaag cttgacattc gctagtcctc tttttcacaa tgaacaggcc ta #tctctgag  41100 ccttctgcag gcaatggtga ctaactacca tctgatgaca ttttgttttg tt #ttgttttg  41160 ttttgagacg gagtttcgct tttgtcaccc gggctggagt gcagtggcac ga #tcttggct  41220 cactgcaacc tctgcctcct gagttcaagc gattctgcct cagcctcctg ag #tagctggg  41280 actacaggca tgcgctacca tgcccagcta attttttgta tttttagtag ag #acggggtt  41340 tccgtgttgg ccaggcttgt ctcgaactcc tgacctcggg tgatccaccc gc #ctcggcct  41400 cccaaagtgt tgggattaca ggcatgagcc accgcgccca gcctgatgac at #agatgctc  41460 cctgatttgc actggggtta gataaacctg ataaacccat tgcccattgt aa #attgaaaa  41520 tatcataagt tggtcaggcg cagtggctga agcccataat cccagcacct tg #ggaggcca  41580 aggtaggcag attgcttgag cccaggagtt caagaccagc ctgggcaatg ta #tctctaca  41640 aaaaatacaa aaattagccg gccatagtga caggtgcttg tagtcccagc tg #gctgctca  41700 ggaggctaag gcaggagaat caattaagct ggggaggtgg aggcttcagt ga #gcattgat  41760 cacgccactg cacttcagct tgggtaacaa tgagaccctg tctcaaaaaa aa #aaaaggaa  41820 gtattgtagg ttgaaaatcc atttaggccg ggcgcagtgg ctcatgcctg ta #atcccaac  41880 aatttgggag gccaaggcag gcggattgct tgaggtcagg agttagagac ca #gcctggcc  41940 aatatggtga aaccccatct ctactaaaaa tacaaaaagt tagcaggaca tg #gtgacaca  42000 cacctgtatt cctagctact tgggaggctg aggcaggaga atcacatgaa cc #cgggaggc  42060 ggaggttgca gtgagccaag atcgtgccat tgcactccag cctgggcgac ag #agcgagac  42120 tctgtctcaa taaataaata agtaaaaata aaaagaatag tacaggtgta at #tgtatgta  42180 cctgtatatg acaaaaagaa aaaaaaaggt gacatagggg aatggggaaa tt #gaagtaga  42240 gaacaggtga agagagggag ctggtgtgaa catgcatggg caggaggaga ca #aatttgta  42300 atgtaatgag gaaatgggtg ggtgagtgat tggcacaggt gaggcttctg ag #ccacctga  42360 gctggtgcag aaggaaggtg ttgatggcag gcaggtaggc tagggggtgc ct #attggagg  42420 aggagtgacc cttgacctgt agggcttgac ctgtttctct ttcctgtgca gc #cattgacc  42480 tcatcaacaa cctgctgcag gtgaagatgc gcaaacgcta cagcgtggac aa #atctctca  42540 gccacccctg gttacaggtg atgcaggggg cagggctggc ccattggctg ga #ttggagga  42600 aggggtggga gtagatcgct tattggctag gcaggttgtg aaggatgtag gt #ttccttgg  42660 gtctggaatg tggctaggcc tcccattggc tgggtgcagg aagagggggt gg #agctaaat  42720 gtctactggc tgggtgggtt gcagagggta tggcttcacc ttcattggta cc #cagctctc  42780 agtggcaaac cagaggatat ccaggcactg ctccaatgca gaccccaagc ta #accccagt  42840 tctctcgggc ccaggagtac cagacgtggc tggacctccg agagctggag gg #gaagatgg  42900 gagagcgata catcacgcat gagagtgacg acgcgcgctg ggagcagttt gc #agcagagc  42960 atccgctgcc tgggtctggg ctgcccacgg acagggatct cggtggggcc tg #tccaccac  43020 aggaccacga catgcagggg ctggcggagc gcatcagtgt tctctgaggt cc #tgtgccct  43080 cgtccagctg ctgccctcca cagcggttct tcacaggatc ccagcaatga ac #tgttctag  43140 ggaaagtggc ttcctgccca aactggatgg gacacgtggg gagtggggtg gg #gggagcta  43200 tttccaaggc ccctccctgt ttccccagca attaaaacgg actcatctct gg #ccccatgg  43260 ccttgatctc agcacacggc actctcgaat cattactctg ttgtaccaac at #ggagttca  43320 tctggaagga ggactgcctg aaaagaggaa ggatggaagg ggtggggaga ga #ggactgat  43380 gggagaggag tcttggaagg aggacgagct ggggtagaaa atatacagga ag #agtgccag  43440 gagagaagat gagaagggag agggaggagt aatggaggag gagttggaaa ct #ggggagag  43500 atggaaggaa tgtgactgga gggtagagaa cttggagaaa aagtaatctc at #ggtttgtg  43560 atgactgatt ttttatttgg tggtggtgtt actactaatc acaactatta at #tcaggctg  43620 ggtgtggtgg ctcatgccta taatcccagc aatttgggag gccgaggcag gc #agatccct  43680 tagatctcag gagtttgaga gcagcctggc caacgtggtg aaactccctt tc #tacaaaaa  43740 gttcaaaaat tagccaagtg tggtggcttg cacctgtggt cccagctact tg #gaggttga  43800 ggctagagga tcgcttgagc ccaggaagca gagattgcag tgagccaaga tc #acacacca  43860 ctgcactcta gcctgggcaa gagagtgaga ccctgtctca aaagtcaaat aa #taaaatgc  43920 agttagccca agtctgatcc atactagaaa          #                   #        43950 <210> SEQ ID  NO 4 <211> LENGTH: 894 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Ala Ala Ala Ala Ala Ala Ala Ala Leu Val Pr #o Gly Ser Gly Pro Gly  1               5   #                10   #                15 Pro Ala Pro Phe Leu Ala Pro Val Ala Ala Pr #o Val Gly Gly Ile Ser             20       #            25       #            30 Phe His Leu Gln Ile Gly Leu Ser Arg Glu Pr #o Val Leu Leu Leu Gln         35           #        40           #        45 Asp Ser Ser Gly Asp Tyr Ser Leu Ala His Va #l Arg Glu Met Ala Cys     50               #    55               #    60 Ser Ile Val Asp Gln Lys Phe Pro Glu Cys Gl #y Phe Tyr Gly Met Tyr 65                   #70                   #75                   #80 Asp Lys Ile Leu Leu Phe Arg His Asp Pro Th #r Ser Glu Asn Ile Leu                 85   #                90   #                95 Gln Leu Val Lys Ala Ala Ser Asp Ile Gln Gl #u Gly Asp Leu Ile Glu             100       #           105       #           110 Val Val Leu Ser Arg Ser Ala Thr Phe Glu As #p Phe Gln Ile Arg Pro         115           #       120           #       125 His Ala Leu Phe Val His Ser Tyr Arg Ala Pr #o Ala Phe Cys Asp His     130               #   135               #   140 Cys Gly Glu Met Leu Trp Gly Leu Val Arg Gl #n Gly Leu Lys Cys Glu 145                 1 #50                 1 #55                 1 #60 Gly Cys Gly Leu Asn Tyr His Lys Arg Cys Al #a Phe Lys Ile Pro Asn                 165   #               170   #               175 Asn Cys Ser Gly Val Arg Arg Arg Arg Leu Se #r Asn Val Ser Leu Thr             180       #           185       #           190 Gly Val Ser Thr Ile Arg Thr Ser Ser Ala Gl #u Leu Ser Thr Ser Ala         195           #       200           #       205 Pro Asp Glu Pro Leu Leu Gln Lys Ser Pro Se #r Glu Ser Phe Ile Gly     210               #   215               #   220 Arg Glu Lys Arg Ser Asn Ser Gln Ser Tyr Il #e Gly Arg Pro Ile His 225                 2 #30                 2 #35                 2 #40 Leu Asp Lys Ile Leu Met Ser Lys Val Lys Va #l Pro His Thr Phe Val                 245   #               250   #               255 Ile His Ser Tyr Thr Arg Pro Thr Val Cys Gl #n Tyr Cys Lys Lys Leu             260       #           265       #           270 Leu Lys Gly Leu Phe Arg Gln Gly Leu Gln Cy #s Lys Asp Cys Arg Phe         275           #       280           #       285 Asn Cys His Lys Arg Cys Ala Pro Lys Val Pr #o Asn Asn Cys Leu Gly     290               #   295               #   300 Glu Val Thr Ile Asn Gly Asp Leu Leu Ser Pr #o Gly Ala Glu Ser Asp 305                 3 #10                 3 #15                 3 #20 Val Val Met Glu Glu Gly Ser Asp Asp Asn As #p Ser Glu Arg Asn Ser                 325   #               330   #               335 Gly Leu Met Asp Asp Met Glu Glu Ala Met Va #l Gln Asp Ala Glu Met             340       #           345       #           350 Ala Met Ala Glu Cys Gln Asn Asp Ser Gly Gl #u Met Gln Asp Pro Asp         355           #       360           #       365 Pro Asp His Glu Asp Ala Asn Arg Thr Ile Se #r Pro Ser Thr Ser Asn     370               #   375               #   380 Asn Ile Pro Leu Met Arg Val Val Gln Ser Va #l Lys His Thr Lys Arg 385                 3 #90                 3 #95                 4 #00 Lys Ser Ser Thr Val Met Lys Glu Gly Trp Me #t Val His Tyr Thr Ser                 405   #               410   #               415 Lys Asp Thr Leu Arg Lys Arg His Tyr Trp Ar #g Leu Asp Ser Lys Cys             420       #           425       #           430 Ile Thr Leu Phe Gln Asn Asp Thr Gly Ser Ar #g Tyr Tyr Lys Glu Ile         435           #       440           #       445 Pro Leu Ser Glu Ile Leu Ser Leu Glu Pro Va #l Lys Thr Ser Ala Leu     450               #   455               #   460 Ile Pro Asn Gly Ala Asn Pro His Cys Phe Gl #u Ile Thr Thr Ala Asn 465                 4 #70                 4 #75                 4 #80 Val Val Tyr Tyr Val Gly Glu Asn Val Val As #n Pro Ser Ser Pro Ser                 485   #               490   #               495 Pro Asn Asn Ser Val Leu Thr Ser Gly Val Gl #y Ala Asp Val Ala Arg             500       #           505       #           510 Met Trp Glu Ile Ala Ile Gln His Ala Leu Me #t Pro Val Ile Pro Lys         515           #       520           #       525 Gly Ser Ser Val Gly Thr Gly Thr Asn Leu Hi #s Arg Asp Ile Ser Val     530               #   535               #   540 Ser Ile Ser Val Ser Asn Cys Gln Ile Gln Gl #u Asn Val Asp Ile Ser 545                 5 #50                 5 #55                 5 #60 Thr Val Tyr Gln Ile Phe Pro Asp Glu Val Le #u Gly Ser Gly Gln Phe                 565   #               570   #               575 Gly Ile Val Tyr Gly Gly Lys His Arg Lys Th #r Gly Arg Asp Val Ala             580       #           585       #           590 Ile Lys Ile Ile Asp Lys Leu Arg Phe Pro Th #r Lys Gln Glu Ser Gln         595           #       600           #       605 Leu Arg Asn Glu Val Ala Ile Leu Gln Asn Le #u His His Pro Gly Val     610               #   615               #   620 Val Asn Leu Glu Cys Met Phe Glu Thr Pro Gl #u Arg Val Phe Val Val 625                 6 #30                 6 #35                 6 #40 Met Glu Lys Leu His Gly Asp Met Leu Glu Me #t Ile Leu Ser Ser Glu                 645   #               650   #               655 Lys Gly Arg Leu Pro Glu His Ile Thr Lys Ph #e Leu Ile Thr Gln Ile             660       #           665       #           670 Leu Val Ala Leu Arg His Leu His Phe Lys As #n Ile Val His Cys Asp         675           #       680           #       685 Leu Lys Pro Glu Asn Val Leu Leu Ala Ser Al #a Asp Pro Phe Pro Gln     690               #   695               #   700 Val Lys Leu Cys Asp Phe Gly Phe Ala Arg Il #e Ile Gly Glu Lys Ser 705                 7 #10                 7 #15                 7 #20 Phe Arg Arg Ser Val Val Gly Thr Pro Ala Ty #r Leu Ala Pro Glu Val                 725   #               730   #               735 Leu Arg Asn Lys Gly Tyr Asn Arg Ser Leu As #p Met Trp Ser Val Gly             740       #           745       #           750 Val Ile Ile Tyr Val Ser Leu Ser Gly Thr Ph #e Pro Phe Asn Glu Asp         755           #       760           #       765 Glu Asp Ile His Asp Gln Ile Gln Asn Ala Al #a Phe Met Tyr Pro Pro     770               #   775               #   780 Asn Pro Trp Lys Glu Ile Ser His Glu Ala Il #e Asp Leu Ile Asn Asn 785                 7 #90                 7 #95                 8 #00 Leu Leu Gln Val Lys Met Arg Lys Arg Tyr Se #r Val Asp Lys Thr Leu                 805   #               810   #               815 Ser His Pro Trp Leu Gln Asp Tyr Gln Thr Tr #p Leu Asp Leu Arg Glu             820       #           825       #           830 Leu Glu Cys Lys Ile Gly Glu Arg Tyr Ile Th #r His Glu Ser Asp Asp         835           #       840           #       845 Leu Arg Trp Glu Lys Tyr Ala Gly Glu Gln Ar #g Leu Gln Tyr Pro Thr     850               #   855               #   860 His Leu Ile Asn Pro Ser Ala Ser His Ser As #p Thr Pro Glu Thr Glu 865                 8 #70                 8 #75                 8 #80 Glu Thr Glu Met Lys Ala Leu Gly Glu Arg Va #l Ser Ile Leu                 885   #               890 

That which is claimed is:
 1. An isolated polypeptide having an amino acid sequence consisting of SEQ ID NO:2.
 2. An isolated serine/threonine kinase having an amino acid sequence comprising SEQ ID NO:2.
 3. A composition comprising the polypeptide of claim 1 and a carrier.
 4. A composition comprising the serine/threonine kinase of claim 2 and a carrier.
 5. The isolated polypeptide of claim 1, wherein residue 835 is valine.
 6. The isolated serine/threonine kinase of claim 2, wherein residue 835 is valine.
 7. A composition comprising the polypeptide of claim 5 and a carrier.
 8. A composition comprising the serine/threonine kinase of claim 6 and a carrier. 